| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Icon Plc$163.57
-1.97 (-1.19%)
B 67Pipeline Score Tools & Services · Commercial
Market Cap
8.16 B
EPS
7.43
P/E Ratio
14.44 $
Value Trade
196.69 M
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
871.92 K
52 Week Range
66.57 - 211.00
% held by Insiders
0.93 %
% held by Institutions
106.46 %
Enterprise Value
11.22 B
Total Shares
76.54 M
Short %
3.41 %
Float Shares
76.16 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Icon Plc
262Total events
0Upcoming
55Tier-1 (high impact)
2007 – 2026Coverage
Event history 2
TBD
▲Partnership / LicenseCorporate
Subscribe to view catalyst details
TBD
▲Partnership / LicenseCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
B67
Pipeline Score $10.5B
Pipeline ValueValuation Signal
50
Drugs Scored1.3x
rNPV / MCap Top 94%
Small Cap (rank 56 of 913)
Percentile RankIcon Plc holds a solid B-grade pipeline (67/100), with $16.4B risk-adjusted pipeline value, led by Apabetalone in Diabetes Mellitus, Type 2 (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apabetalone Small molecule | Diabetes Mellitus, Type 2 | Phase 3 | NCT02586155 | 48% | $6.2B | COMPLETED | 2,425 | - | - | Jun 21, 2021 | - | Aug 20, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ICLR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ICLR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ICLR
Jul 28, 2026▲ +6.8%on this news
ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials
ICON plc has announced a multi-year partnership with Anthropic to integrate AI capabilities into the clinical trial process. This collaboration aims to enhance ICON's digital innovation and AI strategy by utilizing Anthropic's advanced technologies. The partnership is expected to streamline and accelerate various aspects of clinical trials.
Read more →-ICLR
Jun 22, 2026ICON selects Microsoft as a preferred technology partner to power AI-enabled clinical development
ICON has selected Microsoft as its preferred technology partner to enhance AI-enabled clinical development. This partnership is expected to leverage Microsoft's advanced technology to improve the efficiency and effectiveness of clinical trials. The collaboration aims to innovate and streamline processes within the clinical development landscape.
Read more →-ICLR
May 28, 2026▲ +15.5%on this news
ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation
ICON plc reported its financial results for Q4 and full year 2025, highlighting strong net bookings and a positive demand environment. The Audit Committee concluded its investigation into accounting practices, identifying material weaknesses in internal controls. Despite a decrease in earnings per share, ICON anticipates sustainable growth through strategic investments and partnerships.
Read more →-ICLR
May 13, 2026ICON expands US early phase research capabilities with new clinic and outpatient centres
ICON has announced the expansion of its early phase research capabilities in the US by opening new clinic and outpatient centers. This strategic move aims to enhance their service offerings and cater to the growing demand for early phase clinical trials. The expansion reflects ICON's commitment to advancing research in the biopharma sector.
Read more →-ICLR
Feb 12, 2026▼ -39.9%on this news
ICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting Practices
ICON plc announced the timing for its fourth quarter and full year 2025 earnings results, expected by April 30, 2026. The company is undergoing an internal investigation into its accounting practices, focusing on revenue recognition from 2023 to 2025. Preliminary findings suggest minor overstatements in revenue, and the company has withdrawn its financial guidance for 2025.
Read more →-ICLR
Jan 27, 2026ICON’s Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership
ICON plc has announced the opening of the Brian Moran Cancer Institute at Duly Health and Care in Illinois, enhancing its Accellacare Site Network's oncology research capabilities. This partnership aims to improve patient access to innovative cancer treatments and address recruitment challenges in oncology trials. The institute features a team of specialized oncologists and surgical specialists.
Read more →-ICLR
Jan 7, 2026ICON plc update on issuance of full-year 2026 guidance On
ICON plc has announced its intention to issue full-year 2026 guidance alongside the fourth quarter and full-year 2025 results. This decision follows prior updates on the timing of the guidance issuance. The announcement contains forward-looking statements that are based on current expectations and subject to various risks and uncertainties, which may lead to actual results differing from those projected. Investors are advised to exercise caution regarding these statements.
Read more →-ICLR
Mar 3, 2025ICON plc Provides Update on Vaccine Study On
ICON plc announced a delay in their large-scale next generation COVID vaccine study by 90 days, which will impact their revenue for the first half of 2025. Despite this setback, the company maintains its financial guidance for the full year of 2025. The delay was highlighted during an earnings call, indicating ongoing challenges with the study's timeline. The situation emphasizes the uncertainties surrounding clinical studies and their implications on financial performance.
Read more →-ICLR
Apr 25, 2024Document THIRD AMENDMENT TO CREDIT AGREEMENT This THIRD AMENDMENT to the Credit Agreement referred to below, dated as of
ICON Luxembourg S.R.L. and its subsidiaries have executed a third amendment to their Credit Agreement, enabling them to refinance existing term loans. This amendment allows for up to $2.38 billion in Repriced Lux Term Loans and approximately $593 million in Repriced U.S. Term Loans. The refinancing aims to consolidate their financial position while reaffirming obligations to lenders. The amendment underscores a collaborative effort between the company and various financial institutions to enhance financial stability.
Read more →-ICLR
Jan 30, 2024ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call DUBLIN--(BUSINESS WIRE)
ICON plc has announced the schedule for its fourth quarter and full year 2023 earnings conference call, set for February 22, 2024. The financial results will be disclosed after market closure on February 21, 2024. This announcement underscores ICON's commitment to transparency with its stakeholders. The company is poised to share insights and updates on its performance alongside future expectations amidst market uncertainties.
Read more →-ICLR
Jan 9, 2024ICON Issues Financial Guidance for Full Year 2024 Highlights Full Year 2024 Revenue guidance in the range of $8,400 - $8,800 million, representing growth of 3.2% - 8.1% over Full Year 2023 Revenue guidance midpoint. Full
ICON plc released its financial guidance for the full year of 2024, projecting revenue between $8,400 million to $8,800 million, reflecting a growth rate of 3.2% to 8.1% over the previous year. Additionally, the company estimates adjusted earnings per share to range from $14.50 to $15.30, indicating an anticipated growth of 13.5% to 19.8% compared to 2023. CEO Dr. Steve Cutler emphasized the strengthened market position of ICON as a leading provider of clinical development services, attributing growth to increased operational efficiency and innovative tools in clinical research. Despite prevailing macroeconomic challenges, ICON's outlook remains positive for 2024.
Read more →-ICLR
Jan 4, 2024ICON plc to Present at the 42 nd Annual J.P. Morgan Healthcare Conference DUBLIN--(BUSINESS WIRE)
ICON plc, a leading clinical research organization, announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference, with CEO Dr. Steve Cutler scheduled to present on January 9, 2024. The company noted that any changes to the event and links to webcasts will be provided on their Investor Relations website. This involvement at a key industry event underscores ICON's prominence in advancing clinical research and innovations within healthcare.
Read more →-ICLR
Dec 7, 2023ICON Secures Upgraded Credit Rating from Moody's Investors Service DUBLIN--(BUSINESS WIRE)
ICON plc has announced that Moody's Investors Service has upgraded its instrument ratings to Baa3 with a stable outlook, indicating an investment grade financial profile. This positive change is attributed to ICON's strong operating performance and conservative financial strategies. The upgrade is also expected to facilitate a restructuring of existing debt, which could significantly lower interest costs. This upgrade follows a similar enhancement from S&P, reinforcing ICON's financial standing in the market.
Read more →-ICLR
Nov 8, 2023ICON plc to Present at Upcoming Investor Conferences DUBLIN--(BUSINESS WIRE)
ICON plc has announced the presentation of its CFO, Brendan Brennan, at two upcoming investor conferences: the Jefferies London Healthcare Conference on November 14, 2023, and the Evercore HealthCONx Conference on November 29, 2023. This initiative reflects the company's commitment to transparency and investor engagement. ICON plc, based in Dublin and employing over 41,000 people globally, is a renowned clinical research organization dedicated to advancing healthcare and improving patient outcomes. The company has provided details on potential changes regarding the conferences on its investor relations page.
Read more →-ICLR
Oct 25, 2023ICON Reports Third Quarter 2023 Results Highlights Net business wins in the quarter of $2,581 million; a net book to bill of 1.26 or 1.22 on a trailing twelve month basis and an increase of 10% on quarter three 2022. Clo
ICON plc reported strong financial results for the third quarter of 2023, with net business wins reaching $2.58 billion and an increase in revenue of 5.8% compared to the previous year. The company also noted a solid adjusted EBITDA growth of 13.9%. In addition, ICON's recent acquisition of Philips Pharma Solutions and an upgrade to investment grade credit rating by S&P Global Ratings contribute positively to its outlook. The company reaffirmed its full-year 2023 financial guidance, indicating a stable trajectory for growth.
Read more →-ICLR
Oct 12, 2023ICON Secures Upgraded Credit Rating from S&P Global Ratings DUBLIN--(BUSINESS WIRE)
ICON plc has been upgraded by S&P Global Ratings to a credit rating of BBB- with a stable outlook, reflecting the company's strong operating performance and successful debt management. The rating upgrade is attributed to ICON's effective cost synergies from the integration of PRA Health Sciences and a focus on maintaining profitable client relationships. The Chief Financial Officer expressed pride in the upgrade, affirming it aligns with the company's long-term financial strategy. This upgrade positions ICON favorably in the financial market.
Read more →-ICLR
Sep 21, 2023ICON plc Schedules Third Quarter 2023 Earnings Conference Call DUBLIN--(BUSINESS WIRE)
ICON plc has announced the schedule for its third quarter 2023 earnings conference call, which is set to take place on October 26, 2023. The company will release its financial results after the market closes on October 25, 2023. Participants can access the live webcast through the Investor section of ICON's website. The announcement also highlights various forward-looking statements, reminding investors of potential risks and uncertainties that may affect the company's performance.
Read more →-ICLR
Sep 6, 2023ICON plc to Present at the Baird Global Healthcare Conference DUBLIN--(BUSINESS WIRE)
ICON plc announced that CEO Dr. Steve Cutler will present at the Baird Global Healthcare Conference on September 13, 2023. The company, a top clinical research organization, provides services in drug development and healthcare intelligence. ICON has a strong workforce of approximately 41,160 employees distributed across 108 locations in 53 countries. However, the company cautions investors that its forward-looking statements are subject to risks and uncertainties that could affect future performance.
Read more →-ICLR
Jul 28, 2023SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT to the Credit Agreement referred to below, dated as of
ICON Clinical Research and its associates have amended their Credit Agreement to increase Revolving Commitments by $200 million. This adjustment reflects the Revolving Borrowers' request for additional funding while maintaining terms similar to existing loans. The amendment also includes an increase of $75 million to Swingline Loans, ensuring flexibility in their financial operations.
Read more →-ICLR
Jul 26, 2023ICON Reports Second Quarter 2023 Results Highlights Net business wins in the quarter of $2,419 million; a net book to bill of 1.20 or 1.21 on a trailing twelve month basis. Closing backlog of $21.7 billion, an increase o
ICON plc reported its financial results for the second quarter of 2023, highlighting a net business win of $2,419 million and revenue of $2,020.3 million, both reflecting year-over-year growth. The company also increased its adjusted EBITDA by 16.9% and adjusted earnings per share to $3.11. As part of its outlook, ICON revised its full-year 2023 guidance for revenue to a range of $8,070 - $8,210 million, signaling confidence in continued growth.
Read more →-ICLR
Jul 26, 2023ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting DUBLIN--(BUSINESS WIRE)
ICON plc announced that all resolutions proposed at its Annual General Meeting held on July 25, 2023, were passed by shareholders. The resolutions included the re-election of key board members and authorization for various company activities. The strong support from shareholders indicates confidence in ICON's board and direction. This outcome reflects positively on the company's governance and future strategies.
Read more →-ICLR
Jul 5, 2023ICON plc Annual General Meeting of Shareholders to be held on
ICON plc is holding its Annual General Meeting (AGM) on July 25, 2023, in Dublin, Ireland. During this meeting, the company seeks shareholder support for the re-election of eight director nominees and a resolution regarding auditor remuneration. However, recommendations from ISS and GL suggest voting against the re-election of current audit committee members due to concerns over the high proportion of non-audit services provided by KPMG. ICON has responded by clarifying the nature of these fees and asserting that they were necessary for their post-merger integration efforts with PRA Health Sciences.
Read more →-ICLR
Jun 27, 2023ICON plc Schedules Second Quarter 2023 Earnings Conference Call DUBLIN--(BUSINESS WIRE)
ICON plc has announced that it will release its financial results for the second quarter of 2023 on July 26, 2023, after market close. A conference call and webcast to discuss these results will be held on July 27, 2023, at 8:00 am ET. The organization emphasizes its role in advancing clinical research and improving patient lives, maintaining a strong workforce across multiple countries. The press release also notes that forward-looking statements are subject to various risks and uncertainties, reminding investors to consider these factors.
Read more →-ICLR
Jun 26, 2023ICON plc Set to Join Russell 3000 Index DUBLIN--(BUSINESS WIRE)
ICON plc is set to join the Russell 3000 Index, effective after the US market opens today. This inclusion is part of the Russell indexes' annual reconstitution and will enhance ICON's visibility in the market. Membership in the Russell 3000 means automatic inclusion in either the large-cap Russell 1000 or small-cap Russell 2000 indexes, benefiting the company's investment profile. ICON, a leading healthcare intelligence and clinical research organization, employs approximately 41,150 people across 53 countries.
Read more →-ICLR
May 31, 2023ICON plc to Attend Upcoming Investor Conferences DUBLIN--(BUSINESS WIRE)
ICON plc, a leading clinical research organization, has announced participation in upcoming investor conferences, with CEO Dr. Steve Cutler presenting at the William Blair Annual Growth Stock Conference and CFO Mr. Brendan Brennan attending the UBS Healthcare Services Conference. The company highlighted its role in advancing clinical research and developing innovations across various healthcare sectors. However, the release includes forward-looking statements that acknowledge potential risks and uncertainties that could impact future results.
Read more →-ICLR
May 16, 2023ICON releases its 2022 ICON Cares ESG Report DUBLIN--(BUSINESS WIRE)
ICON plc has released its 2022 ICON Cares ESG Report, highlighting significant advancements in its environmental, social, and governance initiatives. The report details achievements such as a silver medal from EcoVadis and a focus on increasing access to clinical trials. Additionally, ICON aims to improve diversity in the workplace, achieving a notable percentage of female leadership promotions. The report also outlines efforts to reduce greenhouse gas emissions and provide community support through scholarship programs.
Read more →-ICLR
Apr 26, 2023ICON Reports First Quarter 2023 Results Highlights Net business wins in the quarter of $2,415 million; a net book to bill of 1.22. Closing backlog of $21.2 billion, an increase of 2.4% on quarter four 2022 or an increase
ICON plc reported a robust first quarter for 2023, highlighting net business wins of $2,415 million and a book-to-bill ratio of 1.22. The company's revenue reached $1,978.6 million, reflecting a 4.0% increase over the prior year, with adjusted EBITDA growing by 17.2%. Additionally, the closing backlog rose to $21.2 billion, indicating strong demand for their services. Despite a projected rise in interest expenses, ICON reaffirmed its guidance for full-year revenue between $7,940 and $8,340 million.
Read more →-ICLR
Mar 29, 2023ICON plc Schedules First Quarter 2023 Earnings Conference Call DUBLIN--(BUSINESS WIRE)
ICON plc announced that it will release its first-quarter 2023 financial results on April 26, 2023, after market closure. A conference call to discuss performance will be held on April 27, 2023. The organization emphasizes its major role in clinical research globally and highlights potential risks and uncertainties associated with its operations, including the impact of market conditions and COVID-19.
Read more →-ICLR
Feb 22, 2023ICON Reports Fourth Quarter and Full Year 2022 Results Highlights Net business wins in the quarter of $2,350 million; a net book to bill of 1.20. Full year net business wins of $9,450 million; a net book to bill of 1.22.
ICON plc reported strong financial results for the fourth quarter and full year of 2022, highlighting net business wins and revenue growth. The company achieved a record adjusted EBITDA of $405 million for the fourth quarter, demonstrating a healthy year-over-year increase. Additionally, ICON reaffirmed its revenue guidance for full year 2023, reflecting continued demand for its services. Despite positive performance, the resignation of a board member and a decrease in cash reserves were noted as concerns.
Read more →-ICLR
Jan 26, 2023ICON plc Schedules Fourth Quarter 2022 Earnings Conference Call DUBLIN--(BUSINESS WIRE)
ICON plc has scheduled its fourth quarter earnings conference call for February 23, 2023, following the release of financial results after market close on February 22. The organization emphasizes its role in advancing clinical research and fostering innovations in healthcare. The company remains focused on providing outsourced services to various sectors, ensuring its adaptability amid changing market conditions.
Read more →-ICLR
Jan 10, 2023▲ +7.8%on this news
ICON Issues Financial Guidance for Full Year 2023 Highlights Full Year 2023 Revenue guidance in the range of $7,940 - $8,340 million, representing growth of 3.3% - 6.8% over Full Year 2022 Revenue guidance. Full Year 202
ICON plc has issued its financial guidance for the full year 2023, projecting revenue between $7,940 million and $8,340 million, representing a growth of 3.3% to 6.8% compared to 2022. The adjusted earnings per share guidance is set to be between $12.40 and $13.05, which indicates growth of 6.4% to 10.1% over the previous year. The company reaffirmed its guidance for 2022 revenue and earnings, highlighting a maintained strong operational delivery but acknowledging ongoing macroeconomic challenges.
Read more →-ICLR
Jan 3, 2023ICON plc to Present at the 41 st Annual J.P. Morgan Healthcare Conference DUBLIN, Ireland--(BUSINESS WIRE)
ICON plc will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. The presentation will be led by CEO Dr. Steve Cutler, showcasing ICON's advancements in healthcare intelligence and clinical research. The company emphasizes its role in improving patient lives through innovation and offers outsourced services to various organizations. Forward-looking statements highlight potential risks and uncertainties affecting future performance.
Read more →-ICLR
Nov 23, 2022ICON plc to Present at the 2022 Evercore ISI HealthCONx Conference DUBLIN--(BUSINESS WIRE)
ICON plc to Present at the 2022 Evercore ISI HealthCONx Conference DUBLIN--(BUSINESS WIRE)--November 23, 2022--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will pre
Read more →-ICLR
Nov 2, 2022ICON Reports Third Quarter 2022 Results Highlights Net business wins in the quarter of $2,351 million; a net book to bill of 1.21, and 1.24 on a trailing twelve month basis. Closing backlog of $20.2 billion, an increase
ICON Reports Third Quarter 2022 Results Net business wins in the quarter of $2,351 million; a net book to bill of 1.21, and 1.24 on a trailing twelve month basis. Closing backlog of $20.2 billion, an increase of 1.3% on Q2 2022 or an increase of 9.0% on Q3 2021. Quarter 3 reve
Read more →-ICLR
Sep 26, 2022ICON plc Schedules Third Quarter 2022 Earnings Conference Call DUBLIN--(BUSINESS WIRE)
ICON plc Schedules Third Quarter 2022 Earnings Conference Call DUBLIN--(BUSINESS WIRE)--September 26, 2022--ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced that it will release its financial results for the thi
Read more →-ICLR
Sep 6, 2022ICON Releases its 2021 ESG Report DUBLIN--(BUSINESS WIRE)
ICON Releases its 2021 ESG Report DUBLIN--(BUSINESS WIRE)--September 6, 2022--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its 2021 Environmental, Social and Governance (ESG) Report. The report outlines how
Read more →-ICLR
Aug 31, 2022ICON plc to Present at the 2022 Wells Fargo Healthcare Conference DUBLIN--(BUSINESS WIRE)
ICON plc to Present at the 2022 Wells Fargo Healthcare Conference DUBLIN--(BUSINESS WIRE)--August 31, 2022--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will presen
Read more →-ICLR
Jul 27, 2022ICON Reports Second Quarter 2022 Results Highlights Net business wins in the quarter of $2,323 million; a net book to bill of 1.20, and 1.25 on a trailing twelve month basis. Closing backlog of $20.0 billion, an increase
ICON Reports Second Quarter 2022 Results Net business wins in the quarter of $2,323 million; a net book to bill of 1.20, and 1.25 on a trailing twelve month basis. Closing backlog of $20.0 billion, an increase of 2.1% on Q1 2022 or an increase of 10.7% year over year on a Combi
Read more →-ICLR
Jun 21, 2022ICON plc Schedules Second Quarter 2022 Earnings Conference Call DUBLIN--(BUSINESS WIRE)
ICON plc Schedules Second Quarter 2022 Earnings Conference Call DUBLIN--(BUSINESS WIRE)--June 21, 2022--ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced that it will release its financial results for the second
Read more →-ICLR
May 23, 2022ICON plc to present at the H.C. Wainwright Global Investment Conference and the Jefferies Healthcare Conference DUBLIN--(BUSINESS WIRE)
ICON plc to present at the H.C. Wainwright Global Investment Conference and the Jefferies Healthcare Conference DUBLIN--(BUSINESS WIRE)--May 23, 2022--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Br
Read more →-ICLR
May 3, 2022ICON plc to present at the BofA Securities 2022 Healthcare Conference DUBLIN--(BUSINESS WIRE)
ICON plc to present at the BofA Securities 2022 Healthcare Conference DUBLIN--(BUSINESS WIRE)--May 3, 2022--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will presen
Read more →-ICLR
Apr 27, 2022ICON Reports First Quarter 2022 Results Highlights Record net business wins in the quarter of $2,426 million; a net book to bill of 1.28. Closing backlog of $19.6 billion, an increase of 2.7% on Q4 2021 or an increase of
ICON Reports First Quarter 2022 Results Record net business wins in the quarter of $2,426 million; a net book to bill of 1.28. Closing backlog of $19.6 billion, an increase of 2.7% on Q4 2021 or an increase of 9.8% year over year on a Combined Company basis. Quarter 1 revenue
Read more →-ICLR
Mar 10, 2022ICON plc to Webcast Analyst Day Meeting DUBLIN--(BUSINESS WIRE)
ICON plc to Webcast Analyst Day Meeting DUBLIN--(BUSINESS WIRE)--March 10, 2022--ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will provide a live webcast of its Analyst Day meeting which will take pla
Read more →-ICLR
Feb 22, 2022ICON Reports Fourth Quarter and Full Year 2021 Results Highlights Record net business wins in the quarter of $2,378 million; a net book to bill of 1.26. Full year net business wins of $6,958 million; a net book to bill o
ICON Reports Fourth Quarter and Full Year 2021 Results Record net business wins in the quarter of $2,378 million; a net book to bill of 1.26. Full year net business wins of $6,958 million; a net book to bill of 1.27. Closing backlog of $19.1 billion, an increase of 2.6% on Q3 2
Read more →-ICLR
Feb 17, 2022ICON plc to Present at the 2022 Citi Healthcare Conference DUBLIN--(BUSINESS WIRE)
ICON plc to Present at the 2022 Citi Healthcare Conference DUBLIN--(BUSINESS WIRE)--February 17, 2022--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will pres
Read more →-ICLR
Jan 12, 2022ICON Issues Financial Guidance for Full Year 2022 Highlights Full Year 2022 Revenue guidance in the range of $7,770 - $8,050 million, representing growth of 43 - 46% over Full Year 2021 Revenue guidance. Full Year 2022 a
ICON Issues Financial Guidance for Full Year 2022 Full Year 2022 Revenue guidance in the range of $7,770 - $8,050 million, representing growth of 43 - 46% over Full Year 2021 Revenue guidance. Full Year 2022 adjusted earnings per share guidance in the range of $11.55 - $11.95,
Read more →-ICLR
Jan 5, 2022ICON plc to Present at the 40 th Annual JP Morgan Healthcare Conference DUBLIN, Ireland--(BUSINESS WIRE)
ICON plc to Present at the 40 th Annual JP Morgan Healthcare Conference DUBLIN, Ireland--(BUSINESS WIRE)--January 5, 2022--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of IC
Read more →-ICLR
Nov 22, 2021ICON Releases Environmental, Social and Governance Report The report looks to the future of ESG for the new ICON while highlighting advancements made in 2020 DUBLIN--(BUSINESS WIRE)
ICON Releases Environmental, Social and Governance Report The report looks to the future of ESG for the new ICON while highlighting advancements made in 2020 DUBLIN--(BUSINESS WIRE)--November 22, 2021--ICON plc (NASDAQ:ICLR) announced today the release of its 2020 Environmental
Read more →-ICLR
Nov 5, 2021▼ -5.2%on this news
ICON plc to Present at the 30th Annual Credit Suisse Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference DUBLIN--(BUSINESS WIRE)
ICON plc to Present at the 30th Annual Credit Suisse Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference DUBLIN--(BUSINESS WIRE)--November 5, 2021--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today
Read more →-ICLR
Nov 3, 2021ICON Reports Third Quarter 2021 Results Highlights Record net business wins in the quarter of $2,374 million; a net book to bill of 1.27. Closing backlog of $18.6 billion, an increase of 3% on our Combined Company Backlo
ICON Reports Third Quarter 2021 Results Record net business wins in the quarter of $2,374 million; a net book to bill of 1.27. Closing backlog of $18.6 billion, an increase of 3% on our Combined Company Backlog since the closing of the PRA acquisition on 1 July 2021, or an incr
Read more →-ICLR
Sep 2, 2021ICON plc to Present at the Wells Fargo 16th Annual Healthcare Conference and the Baird Global Healthcare Conference DUBLIN--(BUSINESS WIRE)
ICON plc to Present at the Wells Fargo 16th Annual Healthcare Conference and the Baird Global Healthcare Conference DUBLIN--(BUSINESS WIRE)--September 2, 2021--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced th
Read more →-ICLR
Jul 21, 2021ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting DUBLIN,--(BUSINESS WIRE)
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting DUBLIN,--(BUSINESS WIRE)--July 21, 2021--ICON plc (NASDAQ: ICLR) ("ICON"), a world-leading healthcare intelligence and clinical research organisation, today announced that all resolutions at the A
Read more →-ICLR
Jul 21, 2021ICON Reports Second Quarter 2021 Results Highlights Record net business wins in the quarter of $1,106 million, an increase of 21.6% year on year; a net book to bill of 1.27. Record closing backlog of $10.2 billion, an in
ICON Reports Second Quarter 2021 Results Record net business wins in the quarter of $1,106 million, an increase of 21.6% year on year; a net book to bill of 1.27. Record closing backlog of $10.2 billion, an increase of 12.7% year on year. Quarter 2 reported revenue of $871.2 m
Read more →-ICLR
Jul 1, 2021CREDIT AGREEMENT dated as of
ICON LUXEMBOURG, S. R.L., INDIGO MERGER SUB, INC., ICON CLINICAL RESEARCH LIMITED, ICON GLOBAL TREASURY UNLIMITED COMPANY, ICON US HOLDINGS INC. and ICON CLINICAL INVESTMENTS, LLC, ICON PUBLIC LIMITED COMPANY, as Holdings and a Guarantor, THE SUBSIDIARY GUARANTORS PARTY H
Read more →-ICLR
Jun 17, 2021ICON Announces Pricing of Senior Secured Notes DUBLIN--(BUSINESS WIRE)
ICON Announces Pricing of Senior Secured Notes DUBLIN--(BUSINESS WIRE)--June 17, 2021--ICON plc (NASDAQ: ICLR) ("ICON") announced today in connection with the proposed acquisition by ICON of PRA Health Sciences, Inc. ("PRA") pursuant to which Indigo Merger Sub, Inc., a wholly ow
Read more →-ICLR
Jun 15, 2021ICON Shareholders Vote in Favour of All Resolutions at its Extraordinary General Meeting DUBLIN--(BUSINESS WIRE)
ICON Shareholders Vote in Favour of All Resolutions at its Extraordinary General Meeting DUBLIN--(BUSINESS WIRE)--June 15, 2021--ICON plc (NASDAQ: ICLR) ("ICON"), a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotec
Read more →-ICLR
Jun 14, 2021ICON Announces Private Offering of Senior Secured Notes Dublin, Ireland
ICON Announces Private Offering of Senior Secured Notes Dublin, Ireland, June 14, 2021 - ICON plc (NASDAQ: ICLR) ("ICON") announced today in connection with the proposed acquisition by ICON of PRA Health Sciences, Inc. ("PRA") pursuant to which Indigo Merger Sub, Inc., a wholly
Read more →-ICLR
Jun 14, 2021UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On February 24, 2021, ICON entered into a Merger Agreement with PRA Health Sciences, Inc. ("PRA"), ICON US Holdings Inc., a Delaware corporation and subsidiary of ICON ("US HoldCo"), and Indigo Merger Sub, Inc., a Del
Read more →-ICLR
Jun 8, 2021Disclaimer Cautionary Note Regarding Forward-Looking StatementsThis "Presentation" contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securi
Disclaimer Cautionary Note Regarding Forward-Looking StatementsThis "Presentation" contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securi
Read more →-ICLR
May 25, 2021ICON plc to Present at the Jefferies Virtual Healthcare Conference and the William Blair 41 st Growth Stock Conference DUBLIN--(BUSINESS WIRE)
ICON plc to Present at the Jefferies Virtual Healthcare Conference and the William Blair 41 st Growth Stock Conference DUBLIN--(BUSINESS WIRE)--May 25, 2021--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to ph
Read more →-ICLR
May 5, 2021ICON plc to Present at the BofA Securities 2021 Virtual Healthcare Conference and the UBS Virtual Global Healthcare Conference DUBLIN--(BUSINESS WIRE)
ICON plc to Present at the BofA Securities 2021 Virtual Healthcare Conference and the UBS Virtual Global Healthcare Conference DUBLIN--(BUSINESS WIRE)--May 5, 2021--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation service
Read more →-ICLR
Apr 28, 2021ICON Reports First Quarter 2021 Results Highlights Record net business wins in the quarter of $1,100 million, an increase of 27% year on year; a net book to bill of 1.28. Record closing backlog of $10 billion, an increas
ICON Reports First Quarter 2021 Results Record net business wins in the quarter of $1,100 million, an increase of 27% year on year; a net book to bill of 1.28. Record closing backlog of $10 billion, an increase of 14.0% year on year. Quarter 1 reported revenue of $858.2 millio
Read more →-ICLR
Mar 9, 2021ICON plc to Present at the Barclays Global Healthcare Conference and the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum DUBLIN--(BUSINESS WIRE)
ICON plc to Present at the Barclays Global Healthcare Conference and the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum DUBLIN--(BUSINESS WIRE)--March 9, 2021--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisa
Read more →-ICLR
Feb 24, 2021ICON to acquire PRA Health Sciences, creating a world leader in Healthcare Intelligence and Clinical Research The consolidation brings together two organizations with a history of robust growth and performance ready to b
ICON to acquire PRA Health Sciences, creating a world leader in Healthcare Intelligence and Clinical Research Dublin, Ireland, 24th February 2021- ICON plc, (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmac
Read more →-ICLR
Feb 24, 2021ICON Reports Fourth Quarter and Full Year 2020 Results Highlights Record net business wins in the quarter of $1,080 million; a book to bill of 1.42. Full year net business wins of $3.8 billion; a net book to bill of 1.38
ICON Reports Fourth Quarter and Full Year 2020 Results *before non-recurring charges. Dublin, Ireland, February 24th, 2021 - ICON plc (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, me
Read more →-ICLR
Jan 7, 2021ICON plc to Present at the 39 th Annual JP Morgan Healthcare Conference DUBLIN, Ireland--(BUSINESS WIRE)
ICON plc to Present at the 39 th Annual JP Morgan Healthcare Conference DUBLIN, Ireland--(BUSINESS WIRE)--January 7, 2021--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medica
Read more →-ICLR
Nov 11, 2020ICON Releases First Environmental, Social and Governance Report DUBLIN--(BUSINESS WIRE)
ICON Releases First Environmental, Social and Governance Report DUBLIN--(BUSINESS WIRE)--November 11, 2020--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and go
Read more →-ICLR
Oct 30, 2020ICON plc to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference and Evercore ISI HealthCONx Conference DUBLIN--(BUSINESS WIRE)
ICON plc to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference and Evercore ISI HealthCONx Conference DUBLIN--(BUSINESS WIRE)--October 30, 2020--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation service
Read more →-ICLR
Oct 21, 2020ICON Reports Third Quarter 2020 Results Highlights Record net business wins in the quarter of $990 million; a book to bill of 1.41. Record closing backlog of $9.4 billion, an increase of 11.8% year on year. Quarter 3 rep
ICON Reports Third Quarter 2020 Results Record net business wins in the quarter of $990 million; a book to bill of 1.41. Record closing backlog of $9.4 billion, an increase of 11.8% year on year. Quarter 3 reported revenue of $701.7 million representing a year on year decrease
Read more →-ICLR
Sep 2, 2020ICON plc to Present at Wells Fargo 2020 Virtual Global Healthcare Conference and Baird 2020 Global Healthcare Conference DUBLIN--(BUSINESS WIRE)
ICON plc to Present at Wells Fargo 2020 Virtual Global Healthcare Conference and Baird 2020 Global Healthcare Conference DUBLIN--(BUSINESS WIRE)--September 2, 2020--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation service
Read more →-ICLR
Jul 22, 2020ICON Reports Second Quarter 2020 Results Highlights Robust net business wins in the quarter of $910 million; a book to bill of 1.47. Record closing backlog of $9.1 billion, an increase of 11% year on year. Quarter 2 repo
ICON Reports Second Quarter 2020 Results Robust net business wins in the quarter of $910 million; a book to bill of 1.47. Record closing backlog of $9.1 billion, an increase of 11% year on year. Quarter 2 reported revenue of $620.2 million representing a year on year decrease
Read more →-ICLR
May 27, 2020ICON plc to Present at Jefferies Virtual Healthcare Conference DUBLIN--(BUSINESS WIRE)
ICON plc to Present at Jefferies Virtual Healthcare Conference DUBLIN--(BUSINESS WIRE)--May 27, 2020--ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, toda
Read more →-ICLR
May 13, 2020ICON plc to Present at UBS Virtual Global Healthcare Conference DUBLIN--(BUSINESS WIRE)
ICON plc to Present at UBS Virtual Global Healthcare Conference DUBLIN--(BUSINESS WIRE)--May 13, 2020--ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, tod
Read more →-ICLR
Apr 22, 2020ICON Reports First Quarter 2020 Results Highlights Net business wins in the quarter of $867 million; a book to bill of 1.21. Record closing backlog of $8.7 billion, an increase of 10.4% year on year. Quarter 1 reported r
ICON Reports First Quarter 2020 Results Net business wins in the quarter of $867 million; a book to bill of 1.21. Record closing backlog of $8.7 billion, an increase of 10.4% year on year. Quarter 1 reported revenue of $715.1 million representing a 6.0% year on year increase o
Read more →-ICLR
Apr 3, 2020ICON Signs New Service Agreement With Pfizer DUBLIN--(BUSINESS WIRE)
ICON Signs New Service Agreement With Pfizer DUBLIN--(BUSINESS WIRE)--April 3, 2020--ICON plc, (NASDAQ: ICLR) a leading global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announc
Read more →-ICLR
Mar 3, 2020ICON plc to Present at Barclays Global Healthcare Conference 2020 DUBLIN--(BUSINESS WIRE)
ICON plc to Present at Barclays Global Healthcare Conference 2020 DUBLIN--(BUSINESS WIRE)--March 3, 2020--ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries,
Read more →-ICLR
Feb 19, 2020ICON Acquires MedPass International Acquisition expands ICON's global Medical Device and Diagnostic Research Services DUBLIN--(BUSINESS WIRE)
ICON Acquires MedPass International Acquisition expands ICON's global Medical Device and Diagnostic Research Services DUBLIN--(BUSINESS WIRE)--February 19, 2020--ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmace
Read more →-ICLR
Feb 19, 2020ICON Reports Fourth Quarter and Full Year 2019 Results Highlights Net business wins in the quarter of $930 million; a book to bill of 1.28. Full year net business wins of $3.6 billion, a net book to bill of 1.30. Record
ICON Reports Fourth Quarter and Full Year 2019 Results Net business wins in the quarter of $930 million; a book to bill of 1.28. Full year net business wins of $3.6 billion, a net book to bill of 1.30. Record closing backlog of $8.6 billion, an increase of 11.4% year on year.
Read more →-ICLR
Jan 14, 2020ICON Issues Financial Guidance for Full Year 2020 Highlights Full Year 2020 Revenue guidance in the range of $2,972 - $3,092 million, representing growth of 5.8 - 10.0%. Full Year 2020 Earnings per share guidance in the
ICON Issues Financial Guidance for Full Year 2020 Full Year 2020 Revenue guidance in the range of $2,972 - $3,092 million, representing growth of 5.8 - 10.0%. Full Year 2020 Earnings per share guidance in the range of $7.55 - $7.85, representing growth of 9.7 - 14.1%. Guidance
Read more →-ICLR
Jan 13, 2020ICON plc to Present at 38th Annual J.P. Morgan Healthcare Conference and Issue Financial Guidance for Full Year 2020 DUBLIN--(BUSINESS WIRE)
ICON plc to Present at 38th Annual J.P. Morgan Healthcare Conference and Issue Financial Guidance for Full Year 2020 DUBLIN--(BUSINESS WIRE)--January 13, 2020--ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceuti
Read more →-ICLR
Nov 27, 2019ICON plc to Present at Evercore ISI 2nd Annual HealthCONx Conference DUBLIN--(BUSINESS WIRE)
ICON plc to Present at Evercore ISI 2nd Annual HealthCONx Conference DUBLIN--(BUSINESS WIRE)--November 27, 2019--ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device indus
Read more →-ICLR
Nov 14, 2019ICON plc to Present at Jefferies 2019 London Healthcare Conference DUBLIN--(BUSINESS WIRE)
ICON plc to Present at Jefferies 2019 London Healthcare Conference DUBLIN--(BUSINESS WIRE)--November 14, 2019--ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industr
Read more →-ICLR
Oct 23, 2019ICON's Acquisition of Symphony Clinical Research Acquisition enhances ICON's ability to offer customers hybrid trial solutions and site support services DUBLIN--(BUSINESS WIRE)
ICON's Acquisition of Symphony Clinical Research Acquisition enhances ICON's ability to offer customers hybrid trial solutions and site support services DUBLIN--(BUSINESS WIRE)--October 23, 2019--ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and comm
Read more →-ICLR
Oct 23, 2019ICON Reports Third Quarter 2019 Results Highlights Record net business wins in the quarter of $931 million; a book to bill of 1.31. Quarter 3 reported revenue of $710.4 million. This represents strong year on year growth
ICON Reports Third Quarter 2019 Results Record net business wins in the quarter of $931 million; a book to bill of 1.31. Quarter 3 reported revenue of $710.4 million. This represents strong year on year growth of 8.5% or 9.5% on a constant currency basis. Adjusted earnings per
Read more →-ICLR
Sep 3, 2019ICON plc to Present at Baird's 2019 Global Healthcare Conference DUBLIN--(BUSINESS WIRE)
ICON plc to Present at Baird's 2019 Global Healthcare Conference DUBLIN--(BUSINESS WIRE)--September 3, 2019--ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industrie
Read more →-ICLR
Jul 24, 2019ICON Announces the Appointment of Ms. Julie O'Neill to Board of Directors and Confirms the Retirement of Professor Dermot Kelleher and Mr. Declan McKeon as Non-Executive Directors DUBLIN--(BUSINESS WIRE)
ICON Announces the Appointment of Ms. Julie O'Neill to Board of Directors and Confirms the Retirement of Professor Dermot Kelleher and Mr. Declan McKeon as Non-Executive Directors DUBLIN--(BUSINESS WIRE)--July 24, 2019--ICON plc, (NASDAQ: ICLR) a global provider of drug and devi
Read more →-ICLR
Jul 24, 2019ICON Reports Second Quarter 2019 Results Highlights Net business wins (including pass-through) in the quarter of $901 million; a book to bill of 1.30. Quarter 2 reported revenue of $695.1 million. This represents a year
ICON Reports Second Quarter 2019 Results Net business wins (including pass-through) in the quarter of $901 million; a book to bill of 1.30. Quarter 2 reported revenue of $695.1 million. This represents a year on year increase of 8.3% or 10.5% on a constant currency basis. Repo
Read more →-ICLR
Jun 10, 2019Notice of Annual General Meeting to be held on 23 July 2019 ICON plc (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you s
Notice of Annual General Meeting to be held on 23 July 2019 (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you should consult with your independent financial adviser who, if you
Read more →-ICLR
May 23, 2019ICON's Acquisition of MeDiNova Research Acquisition enhances ICON's patient access in Europe and Africa DUBLIN--(BUSINESS WIRE)
Acquisition of MeDiNova Research enhances ICON's patient access in Europe and Africa DUBLIN--(BUSINESS WIRE)--May 23, 2019--ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical devic
Read more →-ICLR
May 1, 2019ICON Reports First Quarter 2019 Results Highlights Net business wins (including pass-through) in the quarter of $885 million; a book to bill of 1.31. Closing backlog (including pass-through) of $7.9 billion, a year on ye
Reports First Quarter 2019 Results business wins (including pass-through) in the quarter of $885 million; a book to bill of 1.31. backlog (including pass-through) of $7.9 billion, a year on year 1 reported revenue of $675 million. This represents a year on year increase of 8
Read more →-ICLR
Mar 12, 2019ICON to Present at the Barclays Global Healthcare Conference On
ICON to Present at the Barclays Global Healthcare Conference On March 12, 2019, Mr. Brendan Brennan, CFO of ICON plc, will present at the Barclays Global Healthcare Conference 2019. The presentation will be webcast live from 11.15am EDT [3.15pm This public webcast will be ac
Read more →-ICLR
Feb 20, 2019ICON Reports Fourth Quarter and Full Year 2018 Results Highlights Record net business wins* in the quarter of $607 million, a book to bill of 1.25. Full year net business wins* of $2.4 billion, a net book to bill of 1.27
Reports Fourth Quarter and Full Year 2018 Results net business wins* in the quarter of $607 million, a book to bill of 1.25. Full year net business wins* of $2.4 billion, a net book to bill closing backlog* of $5.4 billion, an increase of 9.7% year on year. 4 reported revenue
Read more →-ICLR
Jan 8, 2019ICON Issues Financial Guidance for Full Year 2019 Highlights Full Year 2019 Revenue guidance in the range of $2,735 - $2,835 million, representing growth of 5.2 - 9.0%. Full Year 2019 Earnings per share guidance in the r
Issues Financial Guidance for Full Year 2019 Year 2019 Revenue guidance in the range of $2,735 - $2,835 million, representing growth of 5.2 - 9.0%. Year 2019 Earnings per share guidance in the range of $6.69 - $6.89, representing growth of 10.6 - 13.9%. intention to repurcha
Read more →-ICLR
Nov 28, 2018ICON to Present at Evercore ISI HealthCONx Conference 2018 On
ICON to Present at Evercore ISI HealthCONx Conference 2018 On November 28, 2018, Mr. Brendan Brennan, CFO of ICON plc, will present at the Evercore ISI HealthCONx Conference 2018. The presentation will be webcast live from 3.30pm ET [8:30pm Ireland & UK]. This public webcast wi
Read more →-ICLR
Nov 14, 2018ICON to Present at Jefferies 2018 London Healthcare Conference On
ICON to Present at Jefferies 2018 London Healthcare Conference On November 14, 2018, Mr. Brendan Brennan, CFO of ICON plc, will present at the Jefferies 2018 London Healthcare Conference. The presentation will be webcast live from 3.20pm GMT. This public webcast will be accessi
Read more →-ICLR
Oct 24, 2018ICON Reports Third Quarter 2018 Results Highlights Excluding the impact of ASC 606, record net business wins in the quarter of $605 million, a book to bill of 1.27. Excluding the impact of ASC 606, closing backlog of $5.
Reports Third Quarter 2018 Results the impact of ASC 606, record net business wins in the quarter of $605 million, a book to bill of 1.27. the impact of ASC 606, closing backlog of $5.3 billion, an increase of 3 reported revenue of $655.0 million. Excluding the impact of ASC
Read more →-ICLR
Sep 10, 2018ICON Sell Side Analyst Day Meeting On
ICON Sell Side Analyst Day Meeting On September 10, 2018, ICON plc will hold a sell side Analyst Day meeting and will be webcasting live from 12.30 p.m. EST. The event will include presentations from members of ICON's executive team. It is expected that the presentations, fol
Read more →-ICLR
Jul 27, 2018ICON Confirms Retirement of Co-Founder Dr. Ronan Lambe DUBLIN--(BUSINESS WIRE)
Confirms Retirement of Co-Founder Dr. Ronan Lambe DUBLIN--(BUSINESS WIRE)--July 27, 2018--ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today confirmed, that Dr. Ronan
Read more →-ICLR
Jul 25, 2018ICON Reports Second Quarter 2018 Results Highlights Excluding the impact of ASC 606, record net business wins in the quarter of $600 million; a book to bill of 1.27. Excluding the impact of ASC 606, closing backlog of $5
Reports Second Quarter 2018 Results the impact of ASC 606, record net business wins in the quarter of $600 million; a book to bill of 1.27. the impact of ASC 606, closing backlog of $5.2 billion, an increase of 2 reported revenue of $641.6 million. Excluding the impact of ASC
Read more →-ICLR
Jun 12, 2018Notice of Annual General Meeting to be held on 24 July 2018 ICON plc (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you s
Notice of Annual General Meeting to be held on 24 July 2018 (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you should consult with your independent financial adviser who, if you
Read more →-ICLR
May 2, 2018ICON Reports First Quarter 2018 Results Highlights Excluding the impact of ASC 606, net business wins in the quarter were $590 million; a book to bill of 1.28. Excluding the impact of ASC 606, closing backlog of $5,053 m
Reports First Quarter 2018 Results the impact of ASC 606, net business wins in the quarter were $590 million; a book to bill of 1.28. the impact of ASC 606, closing backlog of $5,053 million, an increase of 17.2% year on year. 1 reported revenue of $620.1 million. Excluding
Read more →-ICLR
Feb 15, 2018ICON Reports Fourth Quarter and Full Year 2017 Results Highlights Quarter 4 gross business wins of $718 million, a gross book to bill of 1.58. Net business wins of $599 million, a net book to bill of 1.32. Full year gros
Reports Fourth Quarter and Full Year 2017 Results 4 gross business wins of $718 million, a gross book to bill of 1.58. Net business wins of $599 million, a net book to bill of 1.32. Full year gross business wins of $2.6 billion, a gross book to bill of 1.50, net business wins
Read more →-ICLR
Jan 9, 2018ICON Issues Financial Guidance for Full Year 2018 Highlights Full Year 2018 Revenue guidance in the range of $1,870 - $1,930 million, representing growth of 7 - 10%. Full Year 2018 Earnings per share guidance in the rang
Issues Financial Guidance for Full Year 2018 Year 2018 Revenue guidance in the range of $1,870 - $1,930 million, representing growth of 7 - 10%. Year 2018 Earnings per share guidance in the range of $5.89 - $6.09, representing growth of 10 - 13%. DUBLIN--(BUSINESS WIRE)--Jan
Read more →-ICLR
Nov 17, 2017ICON Announces Appointment of Ms. Joan Garahy to Board of Directors DUBLIN--(BUSINESS WIRE)
Announces Appointment of Ms. Joan Garahy to Board of Directors DUBLIN--(BUSINESS WIRE)--November 17, 2017--ICON plc, (NASDAQ: ICLR) global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced t
Read more →-ICLR
Oct 26, 2017ICON Reports Third Quarter 2017 Results Highlights Record gross and net business wins of $691 million and $581 million respectively; gross book to bill of 1.57 and net book to bill of 1.32. Backlog of business grew 13% y
Reports Third Quarter 2017 Results gross and net business wins of $691 million and $581 million respectively; gross book to bill of 1.57 and net book to bill of 1.32. Backlog of business grew 13% year on year to $4.78 billion. revenue increased 4.8% to $440 million compared t
Read more →-ICLR
Oct 4, 2017ICON Announces Appointment of Mr. Eugene McCague to Board of Directors DUBLIN--(BUSINESS WIRE)
Announces Appointment of Mr. Eugene McCague to Board of Directors DUBLIN--(BUSINESS WIRE)--October 4, 2017--ICON plc, (NASDAQ: ICLR) global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced
Read more →-ICLR
Jul 27, 2017ICON Acquires Mapi Group Expands ICON's leadership in Health Outcomes Research and Commercialisation Services DUBLIN--(BUSINESS WIRE)
ICON's leadership in Health Outcomes Research and Commercialisation DUBLIN--(BUSINESS WIRE)--July 27, 2017--ICON plc, (NASDAQ:ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced
Read more →-ICLR
Jul 27, 2017ICON Reports Second Quarter 2017 Results Highlights Record net business wins of $563 million; net book to bill of 1.31. Backlog of business grew 10% year on year to $4.44 billion. Net revenue increased 5.0% to $431 milli
Reports Second Quarter 2017 Results net business wins of $563 million; net book to bill of 1.31. Backlog of business grew 10% year on year to $4.44 billion. revenue increased 5.0% to $431 million compared to the same quarter last year, 6.0% on a constant currency basis. cust
Read more →-ICLR
Jun 23, 2017Notice of Annual General Meeting to be held on 25 July 2017 ICON plc (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you s
Notice of Annual General Meeting to be held on 25 July 2017 (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you should consult with your independent financial adviser who, if you
Read more →-ICLR
Apr 27, 2017ICON Reports First Quarter 2017 Results Highlights Record net business wins of $521 million; net book to bill of 1.21. Backlog of business grew 9.1% year on year to $4.31 billion. Net revenue increased 7.8% to $432 milli
Reports First Quarter 2017 Results net business wins of $521 million; net book to bill of 1.21. of business grew 9.1% year on year to $4.31 billion. revenue increased 7.8% to $432 million compared to the same quarter customer revenue concentration reduced from 29% of revenue
Read more →-ICLR
Feb 16, 2017ICON Reports Fourth Quarter and Full Year 2016 Results Highlights Quarter 4 gross business wins of $605 million, a gross book to bill of 1.39. Net business wins of $434 million, a net book to bill of 1.0. Full year gross
Reports Fourth Quarter and Full Year 2016 Results 4 gross business wins of $605 million, a gross book to bill of 1.39. Net business wins of $434 million, a net book to bill of 1.0. Full year gross business wins of $2.3 billion, a gross book to bill of 1.39, net business wins
Read more →-ICLR
Jan 9, 2017ICON Issues Financial Guidance for Full Year 2017 Highlights Full Year 2017 Revenue guidance in the range of $1,700 - $1,750 million, representing growth of 2 - 5%. Full Year 2017 Earnings per share guidance in the range
Issues Financial Guidance for Full Year 2017 Year 2017 Revenue guidance in the range of $1,700 - $1,750 million, representing growth of 2 - 5%. Year 2017 Earnings per share guidance in the range of $5.00 - $5.20, representing growth of 6 - 11%. DUBLIN--(BUSINESS WIRE)--Janua
Read more →-ICLR
Dec 21, 2016ICON Plc Unaudited Interim Financial Statements For the interim period 1 January 2016 to 31 October 2016 Registered number : 145835 ICON Plc Unaudited Interim Company financial statements Contents Page Directors and othe
Financial Statements For the interim period 1 January 2016 to 31 October 2016 Registered number: 145835 Unaudited Interim Company financial statements Contents Page Directors and other information 1 Statement of directors' responsibilities 2 Non-statutory income statement
Read more →-ICLR
Oct 27, 2016CRO AN OIFIG UM CHLARU CUIDEACHTAI COMPANIES REGRISTRATION OFFICE B7 Variation of company capital as prescribed under Section 83(6) Companies Act 2014 (This form also serves as notice of alteration of share capital under
CRO AN OIFIG UM CHLARU CUIDEACHTAI COMPANIES REGRISTRATION OFFICE B7 Variation of company capital as prescribed under Section 83(6) Companies Act 2014 (This form also serves as notice of alteration of share capital under section 92(1) Companies Act 2014) Company number 145835 CRO
Read more →-ICLR
Oct 24, 2016ICON Announces Appointment of Mr. Ronan Murphy to Board of Directors DUBLIN--(BUSINESS WIRE)
Announces Appointment of Mr. Ronan Murphy to Board of Directors DUBLIN--(BUSINESS WIRE)--October 24, 2016--ICON plc, (NASDAQ:ICLR) global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced th
Read more →-ICLR
Oct 20, 2016ICON Announces Executive Leadership Transition Mr. Ciaran Murray to transition to Chairman, effective 1 st March 2017 Dr. Steve Cutler to be appointed Chief Executive Officer, effective 1 st March 2017 DUBLIN--(BUSINESS
Announces Executive Leadership Transition Ciaran Murray to transition to Chairman, effective 1st Steve Cutler to be appointed Chief Executive Officer, effective 1st DUBLIN--(BUSINESS WIRE)--October 20, 2016--ICON plc, (NASDAQ: ICLR) a global provider of drug development solut
Read more →-ICLR
Oct 20, 2016ICON Reports Third Quarter 2016 Results Highlights Net business wins of $510 million; net book to bill of 1.21. Backlog of business grows 11.8% year on year to $4.25 billion. Net revenue increases 6.4% to $420 million in
Reports Third Quarter 2016 Results business wins of $510 million; net book to bill of 1.21. of business grows 11.8% year on year to $4.25 billion. revenue increases 6.4% to $420 million in the quarter. from operations increases 13.7% to 19.3% of revenue before non-recurring
Read more →-ICLR
Sep 19, 2016ICON Completes the Acquisition of Clinical Research Management, Inc. Acquisition extends ICON's presence in the market for government sponsored research and enhances capabilities in Vaccines and Infectious Disease DUBLIN
Completes the Acquisition of Clinical Research Management, Inc. extends ICON's presence in the market for government sponsored research and enhances capabilities in Vaccines and Infectious Disease DUBLIN--(BUSINESS WIRE)--September 19, 2016--ICON plc, (NASDAQ:ICLR) a global p
Read more →-ICLR
Jul 26, 2016ICON Reports Second Quarter 2016 Results Highlights Record net business wins of $502 million, a net book to bill of 1.22. Backlog of business grows 8.6% year on year to surpass $4 billion for the first time. Net revenue
Reports Second Quarter 2016 Results net business wins of $502 million, a net book to bill of 1.22. of business grows 8.6% year on year to surpass $4 billion for the revenue increases 5.7% to $411 million in the quarter. from operations increases 14.5% to $78 million, before n
Read more →-ICLR
Jun 30, 2016ICON to Acquire Clinical Research Management, Inc. Acquisition extends ICON's presence in the market for government sponsored research and enhances capabilities in Vaccines and Infectious Disease DUBLIN--(BUSINESS WIRE)
Acquire Clinical Research Management, Inc. extends ICON's presence in the market for government sponsored research and enhances capabilities in Vaccines and Infectious Disease DUBLIN--(BUSINESS WIRE)--June 30, 2016--ICON plc, (NASDAQ:ICLR) a global provider of drug developmen
Read more →-ICLR
Jun 10, 2016ICON Announces Service Agreement with Pfizer DUBLIN--(BUSINESS WIRE)
Announces Service Agreement with Pfizer DUBLIN--(BUSINESS WIRE)--June 10, 2016--ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced it has signed a three-year agreem
Read more →-ICLR
Jun 10, 2016Notice of Annual General Meeting to be held on 22 July 2016 ICON plc (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you s
Notice of Annual General Meeting to be held on 22 July 2016 (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you should consult with your independent financial adviser who, if you
Read more →-ICLR
Apr 26, 2016ICON Reports First Quarter 2016 Results Highlights Backlog of business up 9% year on year to $3.95 billion Quarter 1 gross business wins of $514 million, a gross book to bill of 1.29. Net business wins of $440 million, a
Reports First Quarter 2016 Results of business up 9% year on year to $3.95 billion 1 gross business wins of $514 million, a gross book to bill of 1.29. Net business wins of $440 million, a net book to bill of 1.10 1 net revenue $401 million, an increase of 3.2% year on year,
Read more →-ICLR
Mar 29, 2016Mr. Thomas Lynch Notifies ICON of His Retirement as Chairman and That He Will Not Stand for Re-Election to the Board of Directors at the Annual General Meeting DUBLIN--(BUSINESS WIRE)
Thomas Lynch Notifies ICON of His Retirement as Chairman and That He Will Not Stand for Re-Election to the Board of Directors at the Annual DUBLIN--(BUSINESS WIRE)--March 29, 2016--ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the ph
Read more →-ICLR
Feb 23, 2016ICON Reports Fourth Quarter and Full Year 2015 Results and Issues 2016 Earnings Guidance Highlights Quarter 4 gross business wins of $565 million, a gross book to bill of 1.40. Net business wins of $471 million, a net bo
Reports Fourth Quarter and Full Year 2015 Results and Issues 2016 4 gross business wins of $565 million, a gross book to bill of 1.40. Net business wins of $471 million, a net book to bill of 1.17. Full year net business wins of $1.9 billion, a net book to bill of 1.20. 4 net
Read more →-ICLR
Jan 5, 2016ICON Secures Investment Grade Credit Ratings DUBLIN--(BUSINESS WIRE)
Secures Investment Grade Credit Ratings DUBLIN--(BUSINESS WIRE)--January 5, 2016--ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported that Moody's Investors Se
Read more →-ICLR
Dec 16, 2015ICON plc Announces Private Placement of US$350,000,000 of Senior Notes DUBLIN--(BUSINESS WIRE)
Announces Private Placement of US$350,000,000 of Senior Notes DUBLIN--(BUSINESS WIRE)--December 16, 2015--ICON plc, (NASDAQ: ICLR), today announced the successful completion and settlement of the private placement by its subsidiary ICON Investment Five Unlimited Company (the
Read more →-ICLR
Dec 7, 2015ICON Acquires PMG Research, Inc. Acquisition enhances ICON's site and patient engagement capabilities DUBLIN--(BUSINESS WIRE)
Acquires PMG Research, Inc. enhances ICON's site and patient engagement capabilities DUBLIN--(BUSINESS WIRE)--December 7, 2015--ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device indust
Read more →-ICLR
Nov 25, 2015ICON Announces the Appointment of Dr. Steve Cutler to Board of Directors DUBLIN--(BUSINESS WIRE)
Announces the Appointment of Dr. Steve Cutler to Board of Directors DUBLIN--(BUSINESS WIRE)--November 25, 2015--ICON plc, (NASDAQ:ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today annou
Read more →-ICLR
Oct 27, 2015ICON Reports Third Quarter 2015 Highlights Gross business wins of $518 million, representing a gross book to bill of 1.31. Net business wins of $475 million, representing a net book to bill of 1.20. Quarter 3 net revenue
Reports Third Quarter 2015 business wins of $518 million, representing a gross book to bill of 1.31. Net business wins of $475 million, representing a net book to 3 net revenue of $395 million, a 1.8% increase year on year and a 4.1% increase on a constant dollar organic basi
Read more →-ICLR
Oct 14, 2015B7 COMPANIES REGISTRATION OFFICE CRO Variation of company capital as prescribed under Section 83(6) Companies Act 2012 (This form also serves as notice of alteration of share capital under section 92(1) Companies Act 201
B7 COMPANIES REGISTRATION OFFICE CRO Variation of company capital as prescribed under Section 83(6) Companies Act 2012 (This form also serves as notice of alteration of share capital under section 92(1) Companies Act 2014) Company number 145835 CRO receipt date stamp & barcode Pl
Read more →-ICLR
Oct 2, 2015cro AN OIFIG UM CHLARU CUIDEACHTAI COMPANIES REGISTRATION OFFICE variation of company capital as prescribed under Section 83(6) Companies Act 2014 (This form also serves as notice of alteration of share capital under sec
cro AN OIFIG UM CHLARU CUIDEACHTAI COMPANIES REGISTRATION OFFICE variation of company capital as prescribed under Section 83(6) Companies Act 2014 (This form also serves as notice of alteration of share capital under section 92(1) Companies Act 2014) B7 CRO receipt date stamp & b
Read more →-ICLR
Sep 4, 2015Crio AN OIFIG UM CHLARU CUIDEACHTAi f --:7 I l COMPANIES REGISTRATION OFflCE :-,.,1 Variation of company capital as prescribed under Section 63(6) Companies Act 2014 (This form also serves as notice of alteration of shar
Crio AN OIFIG UM CHLARU CUIDEACHTAi f --:7 I l COMPANIES REGISTRATION OFflCE :-,.,1 Variation of company capital as prescribed under Section 63(6) Companies Act 2014 (This form also serves as notice of alteration of share capital under section 92(1) Companies Act 2014) Company nu
Read more →-ICLR
Aug 27, 2015ICON Plc Unaudited Interim Financial Statements For the Interim Period from 1 January 2015 to 31 July 2015 Registered number: 145835 These unaudited interim financial statements have been prepared solely to present infor
ICON Plc Unaudited Interim Financial Statements For the Interim Period from 1 January 2015 to 31 July 2015 Registered number: 145835 ICON Plc Unaudited Interim financial statements Contents Page Directors and other information 1 Unaudited interim income statement 2 Unaudit
Read more →-ICLR
Jul 28, 2015ICON Reports Second Quarter 2015 Highlights Gross business wins of $571 million, representing a gross book to bill of 1.47. Net business wins of $486 million, representing a net book to bill of 1.25. Quarter 2 net revenu
Reports Second Quarter 2015 business wins of $571 million, representing a gross book to bill of 1.47. Net business wins of $486 million, representing a net book to 2 net revenue of $389 million, a 3.4% increase year on year and a 4% increase on a constant dollar organic basis
Read more →-ICLR
Jun 12, 2015Notice of Annual General Meeting to be held on 24 July 2015 ICON plc (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you s
Notice of Annual General Meeting to be held on 24 July 2015 (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you should consult with your independent financial adviser who, if you
Read more →-ICLR
Jun 9, 2015shares 01 06 2015 Date effective Description of change Company name Cro AN OIFIG UM CHALARU CUIDEACHTAI COMPANIES REGISTRATION OFFICE Director Secretary note two Name in bold capitals or typescript Section 83(6) Comp
43,036 shares 01 06 2015 Date effective Description of change Company name Cro AN OIFIG UM CHALARU CUIDEACHTAI COMPANIES REGISTRATION OFFICE Director Secretary note two Name in bold capitals or typescript Section 83(6) Companies Act 2014 ICON Public Limited Company in the capital
Read more →-ICLR
Apr 28, 2015ICON Reports First Quarter 2015 Highlights Quarter 1 net revenue increased 11% year on year to $388 million, a 13% increase on a constant organic dollar basis. Income from operations was $66.7 million or 17.2% of revenue
Reports First Quarter 2015 1 net revenue increased 11% year on year to $388 million, a 13% increase on a constant organic dollar basis. from operations was $66.7 million or 17.2% of revenue as reported. Excluding a one off foreign exchange revaluation gain, operating margin
Read more →-ICLR
Mar 2, 2015ICON Completes Acquisition of MediMedia Pharma Solutions Extends ICON's leadership in commercialisation and market access services and brings new scientific communications capabilities DUBLIN--(BUSINESS WIRE)
Completes Acquisition of MediMedia Pharma Solutions ICON's leadership in commercialisation and market access services and brings new scientific communications capabilities DUBLIN--(BUSINESS WIRE)--March 2, 2015--ICON plc (NASDAQ:ICLR), a global provider of drug development so
Read more →-ICLR
Feb 25, 2015ICON Reports Fourth Quarter and Full Year 2014 Results and Issues 2015 Earnings Guidance Highlights Quarter 4 net revenue increased 13.0% year on year to $390 million. Full Year 2014 net revenue increased 12.5% to $1.50
Reports Fourth Quarter and Full Year 2014 Results and Issues 2015 4 net revenue increased 13.0% year on year to $390 million. Full Year 2014 net revenue increased 12.5% to $1.50 billion. 4 income from operations before non-recurring charges was $60.4 million or 15.5% of reven
Read more →-ICLR
Feb 2, 2015ICON to Acquire MediMedia Pharma Solutions Extends ICON's leadership in commercialisation and market access services and brings new scientific communications capabilities DUBLIN--(BUSINESS WIRE)
Acquire MediMedia Pharma Solutions ICON's leadership in commercialisation and market access services and brings new scientific communications capabilities DUBLIN--(BUSINESS WIRE)--February 2, 2015--ICON plc (NASDAQ:ICLR), a global provider of outsourced development services t
Read more →-ICLR
Dec 18, 2014Form No. 28.(B7) Certificate No 145835 COMPANIES ACTS, 1963 TO 2013 NOTICE of CONSOLIDATION and DIVISION, or CONVERSION into STOCK of SHARES, or of the Re-Conversion into Share of Stock, or of the Subdivision or Redempti
TO THE REGISTRAR OF JOINT STOCK COMPANIES ICON PUBLIC LIMITED COMPANY hereby gives you notice in accordance with S.69 of the Companies Acts, 1963 - 2013, that* In a series of transactions during October 2014, as set out below, 210,000 shares in the capital of the Company were red
Read more →-ICLR
Oct 24, 2014Form No. 28.(B7) Certificate No 145835 COMPANIES ACTS, 1963 TO 2013 NOTICE OF CONSOLIDATION and DIVISION, or CONVERSION into STOCK of SHARES, or of the Re-conversion into Share of Stock, or of the Subdivision or Redempti
Certificate No 145835 COMPANIES ACTS, 1963 TO 2013 NOTICE OF CONSOLIDATION and DIVISION, or CONVERSION into STOCK of SHARES, or of the Re-conversion into Share of Stock, or of the Subdivision or Redemption or Cancellation of Shares of ICON Public Limited Company specifying, as
Read more →-ICLR
Oct 22, 2014ICON Reports Third Quarter 2014 and Increases Earnings Guidance Highlights - Third Quarter Fiscal 2014 Net revenue increased 14.1% year on year to $388 million. Income from operations was $59.4 million or 15.3% of revenu
Reports Third Quarter 2014 and Increases Earnings Guidance - Third Quarter Fiscal 2014 revenue increased 14.1% year on year to $388 million. from operations was $59.4 million or 15.3% of revenue. per share were 79 cents. business wins were $504 million, representing a gross
Read more →-ICLR
Sep 19, 2014ICON Plc Announces Completion of $40 Million Share Buyback and a Further Share Buyback Program for up to $100 Million DUBLIN--(BUSINESS WIRE)
Announces Completion of $40 Million Share Buyback and a Further Share Buyback Program for up to $100 Million DUBLIN--(BUSINESS WIRE)--September 19, 2014--ICON plc, (Nasdaq: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and me
Read more →-ICLR
Jul 30, 2014ICON Reports Second Quarter 2014 and Increases Earnings Guidance Highlights - Second Quarter Fiscal 2014 Quarter 2 net revenue increased 12.5% year on year to $376 million. Income from operations was $48.3 million or 12.
Reports Second Quarter 2014 and Increases Earnings Guidance - Second Quarter Fiscal 2014 2 net revenue increased 12.5% year on year to $376 million. from operations was $48.3 million or 12.8% of revenue. per share were 64 cents. business wins were $521 million, representing
Read more →-ICLR
Jun 19, 2014Notice of Annual General Meeting to be held on 29 July 2014 ICON plc (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you s
Notice of Annual General Meeting to be held on 29 July 2014 (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you should consult with your independent financial adviser who, if you
Read more →-ICLR
Jun 6, 2014Form No. 28 (B7) Certificate No145835 COMPANIES ACTS, 1963 TO 2013 NOTICE of CONSOLIDATION and DIVISION, or CONVERSION into STOCK of SHARES, or of the Re-Conversion into Share of Stock, or of the Subdivision or Redemptio
Certificate No145835 COMPANIES ACTS, 1963 TO 2013 NOTICE of CONSOLIDATION and DIVISION, or CONVERSION into STOCK of SHARES, or of the Re-Conversion into Share of Stock, or of the Subdivision or Redemption or Cancellation of Shares of ICON Public Limited Company specifying, as
Read more →-ICLR
May 9, 2014ICON to Webcast Analyst Day Meeting DUBLIN--(BUSINESS WIRE)
Webcast Analyst Day Meeting DUBLIN--(BUSINESS WIRE)--May 9, 2014--ICON plc, (NASDAQ:ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it will provide a live webcast of its Analy
Read more →-ICLR
May 8, 2014ICON Completes Acquisition of Aptiv Solutions DUBLIN--(BUSINESS WIRE)
Completes Acquisition of Aptiv Solutions DUBLIN--(BUSINESS WIRE)--May 8, 2014--ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the previous
Read more →-ICLR
Apr 30, 2014ICON Reports First Quarter 2014 Highlights - First Quarter Fiscal 2014. Quarter 1 net revenue increased 10% year on year to $350 million. Income from operations was $43.0 million or 12.3% of revenue. Earnings per share w
Reports First Quarter 2014 - First Quarter Fiscal 2014. 1 net revenue increased 10% year on year to $350 million. from operations was $43.0 million or 12.3% of revenue. per share were 57 cents. Business wins were $494 million, representing a gross book to bill of 1.41, Net
Read more →-ICLR
Apr 30, 2014ICON Announces Appointment of Dr. Hugh Brady to Board of Directors DUBLIN--(BUSINESS WIRE)
Announces Appointment of Dr. Hugh Brady to Board of Directors DUBLIN--(BUSINESS WIRE)--April 30, 2014--ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appoin
Read more →-ICLR
Mar 31, 2014ICON to Acquire Aptiv Solutions Acquisition enhances ICON's capabilities in adaptive and medical device trials and in Japan DUBLIN--(BUSINESS WIRE)
Acquire Aptiv Solutions enhances ICON's capabilities in adaptive and medical device trials and DUBLIN--(BUSINESS WIRE)--March 31, 2014--ICON plc, (NASDAQ:ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device indust
Read more →-ICLR
Feb 20, 2014ICON Announces Appointment of Ms. Mary Pendergast to Board of Directors DUBLIN--(BUSINESS WIRE)
Announces Appointment of Ms. Mary Pendergast to Board of Directors DUBLIN--(BUSINESS WIRE)--February 20, 2014--ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced th
Read more →-ICLR
Feb 20, 2014ICON Reports Fourth Quarter 2013 Revenue of $345 million, up 15% year on year and EPS of 53c, up 56% year on year. Full Year 2013 Revenue was $1.34 billion, up 20% year on year, EPS was $1.77 up 77% year on year. Guidanc
Reports Fourth Quarter 2013 Revenue of $345 million, up 15% year on year and EPS of 53c, up 56% year on year. Full Year 2013 Revenue was $1.34 billion, up 20% year on year, EPS was $1.77 up 77% year on year. Guidance issued for 2014. - Fourth Quarter and Full year ended Decem
Read more →-ICLR
Jan 24, 2014ICON plc Announces Resignation of a Director On
ICON plc Announces Resignation of a Director On January 24, 2014, ICON plc (the "Company") received notice from its director Ms. Cathrin Petty that she is resigning as a member of the Board of Directors, effective immediately. Ms. Petty is resigning from the Company's board in o
Read more →-ICLR
Oct 24, 2013ICON Reports Third Quarter 2013 Revenue of $340 Million, up 19% Year on Year, EPS of 45C and Raises FY 2013 Guidance. Highlights - Third Quarter Fiscal 2013. Quarter 3 net revenue increased 19% year on year to $340 milli
Reports Third Quarter 2013 Revenue of $340 Million, up 19% Year on Year, EPS of 45C and Raises FY 2013 Guidance. - Third Quarter Fiscal 2013. 3 net revenue increased 19% year on year to $340 million. from operations was $33.2 million or 9.8% of revenue. per share was 45 cent
Read more →-ICLR
Jul 25, 2013ICON Reports second quarter 2013 Revenue of $334 million, up 21% year on year, non-GAAP EPS of 43c and raises FY 2013 Guidance. Highlights - Second Quarter Fiscal 2013. Quarter 2 net revenue increased 21% year on year to
Reports second quarter 2013 Revenue of $334 million, up 21% year on year, non-GAAP EPS of 43c and raises FY 2013 Guidance. - Second Quarter Fiscal 2013. 2 net revenue increased 21% year on year to $334 million. from operations, excluding restructuring charges of $4.6 million,
Read more →-ICLR
Jul 23, 2013ICON shareholders vote in favour of all resolutions at its Annual General Meeting DUBLIN--(BUSINESS WIRE)
shareholders vote in favour of all resolutions at its Annual General DUBLIN--(BUSINESS WIRE)--July 23, 2013--ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that
Read more →-ICLR
Jul 11, 2013Mr Justin Levis ISS 20850 King Farm Boulevard Rockville MD 20850 11 July 2013 ICON plc Annual General Meeting (AGM) Dear Justin Thank you for your engagement in relation to the ISS report on our upcoming AGM. As discusse
20850 King Farm Boulevard ICON plc Annual General Meeting (AGM) Thank you for your engagement in relation to the ISS report on our upcoming AGM. As discussed, ICON feels that resolutions 4 and 5 (which are linked and related resolutions) included in our proxy (the ability to i
Read more →-ICLR
Jun 17, 2013Notice of Annual General Meeting to be held on 22 July 2013 ICON plc (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you s
Notice of Annual General Meeting to be held on 22 July 2013 (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you should consult with your independent financial adviser who, if you
Read more →-ICLR
Apr 25, 2013ICON Reports First Quarter 2013 Revenue of $317 Million, up 26% year on year and non-GAAP EPS of 36c. Highlights - First Quarter Fiscal 2013. Quarter 1 net revenue increased 26% year on year to $317 million. Income from
Reports First Quarter 2013 Revenue of $317 Million, up 26% year on year and non-GAAP EPS of 36c. - First Quarter Fiscal 2013. 1 net revenue increased 26% year on year to $317 million. from operations, excluding restructuring and other items, was $27.4 million or 8.7% of reve
Read more →-ICLR
Feb 21, 2013ICON Announces Appointment of Professor William Hall to Board of Directors DUBLIN--(BUSINESS WIRE)
Announces Appointment of Professor William Hall to Board of Directors DUBLIN--(BUSINESS WIRE)--February 21, 2013--ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced
Read more →-ICLR
Feb 19, 2013ICON Reports Fourth Quarter 2012 Revenue of $300 Million, up 24% year on year, EPS of 34c and Full Year revenue of $1.12 billion, EPS of $1.00. Highlights - Fourth Quarter and Full year ended December 31 2012. Quarter 4
Reports Fourth Quarter 2012 Revenue of $300 Million, up 24% year on year, EPS of 34c and Full Year revenue of $1.12 billion, EPS of $1.00. - Fourth Quarter and Full year ended December 31 2012. 4 net revenue increased 24% year on year to $300 million. Full Year 2012 net reven
Read more →-ICLR
Feb 5, 2013ICON Announces the Commencement of Direct Trading on NASDAQ DUBLIN--(BUSINESS WIRE)
Announces the Commencement of Direct Trading on NASDAQ DUBLIN--(BUSINESS WIRE)--February 5, 2013--ICON plc, (NASDAQ: ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, commenced d
Read more →-ICLR
Feb 4, 2013ICON To Acquire Clinical Trial Services Division of Cross Country Healthcare, Inc. Acquisition Expands ICON's Global Resourcing, FSP and Safety Capabilities DUBLIN--(BUSINESS WIRE)
Acquire Clinical Trial Services Division of Cross Country Healthcare, Expands ICON's Global Resourcing, FSP and Safety Capabilities DUBLIN--(BUSINESS WIRE)--February 4, 2013--ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to
Read more →-ICLR
Dec 21, 2012Mr. Thomas Lynch Elected as Chairman of ICON plc DUBLIN--(BUSINESS WIRE)
Thomas Lynch Elected as Chairman of ICON plc DUBLIN--(BUSINESS WIRE)--December 21, 2012--ICON plc, (NASDAQ: ICLR)(ISIN: IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that
Read more →-ICLR
Dec 18, 2012ICON shareholders vote in favour of all resolutions at its Extraordinary General Meeting relating to the proposed conversion to a direct listing of ICON's shares on NASDAQ DUBLIN--(BUSINESS WIRE)
shareholders vote in favour of all resolutions at its Extraordinary to the proposed conversion to a direct listing of ICON's shares on NASDAQ DUBLIN--(BUSINESS WIRE)--December 18, 2012--ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development s
Read more →-ICLR
Dec 3, 2012ICON plc provides 2013 Financial Guidance ahead of Investor Day in New York DUBLIN--(BUSINESS WIRE)
provides 2013 Financial Guidance ahead of Investor Day in New York DUBLIN--(BUSINESS WIRE)--December 3, 2012--ICON plc. (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries,
Read more →-ICLR
Nov 29, 2012Dr. Bruce Given notifies ICON that he will not seek a further term as Chairman of the Board DUBLIN--(BUSINESS WIRE)
Given notifies ICON that he will not seek a further term as Chairman of DUBLIN--(BUSINESS WIRE)--November 29, 2012--ICON plc. (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device indust
Read more →-ICLR
Nov 23, 2012Notice of Extraordinary General Meeting to be held on 17 December 2012 ICON plc (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION I f you are in any doubt as to the action to be t
Notice of Extraordinary General Meeting to be held on 17 December 2012 (the "Company" or "ICON") THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt as to the action to be taken, you should consult with your independent financial adviser w
Read more →-ICLR
Nov 16, 2012ICON Announces Publication of EGM Circular in Respect of Proposed Conversion to Direct Listing of its Shares on NASDAQ DUBLIN--(BUSINESS WIRE)
Announces Publication of EGM Circular in Respect of Proposed Conversion to Direct Listing of its Shares on NASDAQ DUBLIN--(BUSINESS WIRE)--November 16, 2012--ICON plc, (NASDAQ: ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutic
Read more →-ICLR
Nov 1, 2012ICON Reports Q3 Revenue of $286 Million, EPS of 29c and Net New Business of $450 Million. (NASDAQ: ICLR) (ISIN:IE0005711209) Highlights - Third Quarter Fiscal 2012 Net revenue of $286 million, a 19% increase year on year
Reports Q3 Revenue of $286 Million, EPS of 29c and Net New Business of $450 Million. (NASDAQ: ICLR) (ISIN:IE0005711209) - Third Quarter Fiscal 2012 revenue of $286 million, a 19% increase year on year. from operations of $20.9 million or 7.3% of net revenue. 29 cents on net
Read more →-ICLR
Aug 30, 2012ICON plc and subsidiaries Interim financial statements Six months ended 30 June 2012 Registered number 145835 ICON plc and subsidiaries Interim Management Report and Condensed Consolidated Financial Statements Contents P
ICON plc and subsidiaries Interim financial statements Six months ended 30 June 2012 Registered number145835 ICON plc and subsidiaries Interim Management Report and Condensed Consolidated Financial Statements Contents Page Interim Management report 3 Directors' Responsibili
Read more →-ICLR
Jul 24, 2012ICON Reports second quarter 2012 revenue up 19% to $277 million and non-GAAP EPS of 21c (NASDAQ:ICLR) (ISIN:IE0005711209) Highlights - Second Quarter Fiscal 2012 * Net revenue of $277 million, a 19% increase year on year
Reports second quarter 2012 revenue up 19% to $277 million and non-GAAP EPS of 21c (NASDAQ:ICLR) (ISIN:IE0005711209) - Second Quarter Fiscal 2012 revenue of $277 million, a 19% increase year on year. from operations, excluding restructuring and other non-recurring items, was
Read more →-ICLR
Jul 20, 2012ICON Shareholders Vote in Favour of All Resolutions at Its Annual General Meeting DUBLIN--(BUSINESS WIRE)
Shareholders Vote in Favour of All Resolutions at Its Annual General DUBLIN--(BUSINESS WIRE)--July 20, 2012--ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, t
Read more →-ICLR
Jul 2, 2012July, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 29 June, 2012 it purchased for cancellation 10,2
the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 29 June, 2012 it purchased for cancellation 10,230 Ordinary Shares, at an average price of $21.9196. the cancellation of these shares, the Company will have 59,679
Read more →-ICLR
Jun 27, 2012June, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 26 June, 2012 it purchased for cancellation 23,7
the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 26 June, 2012 it purchased for cancellation 23,700 Ordinary Shares, at an average price of $21.4982. the cancellation of these shares, the Company will have 59,700
Read more →-ICLR
Jun 21, 2012June, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 20 June, 2012 it purchased for cancellation 3,20
the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 20 June, 2012 it purchased for cancellation 3,200 Ordinary Shares, at an average price of $21.9503. the cancellation of these shares, the Company will have 59,743,
Read more →-ICLR
Jun 19, 2012June, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 18 June, 2012 it purchased for cancellation 20,0
the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 18 June, 2012 it purchased for cancellation 20,000 Ordinary Shares, at an average price of $21.5207. the cancellation of these shares, the Company will have 59,749
Read more →-ICLR
Jun 14, 2012June, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 13 June, 2012 it purchased for cancellation 20,0
the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 13 June, 2012 it purchased for cancellation 20,000 Ordinary Shares, at an average price of $21.1622. the cancellation of these shares, the Company will have 59,790
Read more →-ICLR
Jun 14, 2012Dear Shareholders, The market trends that were evident during 2010 accelerated during 2011 as the pressure remained on our clients to reduce research and development costs and national governments sought to further reduc
The market trends that were evident during 2010 accelerated during 2011 as the pressure remained on our clients to reduce research and development costs and national governments sought to further reduce their healthcare budgets. For global Contract Research Organisations such as
Read more →-ICLR
Jun 12, 2012ICON Announces Peter Gray to Retire from ICON Board of Directors DUBLIN--(BUSINESS WIRE)
Announces Peter Gray to Retire from ICON Board of Directors DUBLIN--(BUSINESS WIRE)--June 12, 2012--ICON plc, (NASDAQ:ICLR)(ISIN:IE0005711209) , a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today anno
Read more →-ICLR
Jun 12, 2012June, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 11 June, 2012 it purchased for cancellation 19,5
the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 11 June, 2012 it purchased for cancellation 19,543 Ordinary Shares, at an average price of $21.4245. the cancellation of these shares, the Company will have 59,822
Read more →-ICLR
Jun 8, 2012June, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 7 June, 2012 it purchased for cancellation 17,00
the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 7 June, 2012 it purchased for cancellation 17,000 Ordinary Shares, at an average price of $21.5764. the cancellation of these shares, the Company will have 59,845,
Read more →-ICLR
Jun 6, 2012June, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 5 June, 2012 it purchased for cancellation 22,40
the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 5 June, 2012 it purchased for cancellation 22,400 Ordinary Shares, at an average price of $20.8778. the cancellation of these shares, the Company will have 59,859,
Read more →-ICLR
Jun 1, 2012June, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 31 May, 2012 it purchased for cancellation 20,00
the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 31 May, 2012 it purchased for cancellation 20,000 Ordinary Shares, at an average price of $21.5367. the cancellation of these shares, the Company will have 59,927,
Read more →-ICLR
May 31, 2012May, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 30 May, 2012 it purchased for cancellation 14,339
Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 30 May, 2012 it purchased for cancellation 14,339 Ordinary Shares, at an average price Following the cancellation of these s
Read more →-ICLR
May 29, 2012May, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 25 May, 2012 it purchased for cancellation 20,000
Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 25 May, 2012 it purchased for cancellation 20,000 Ordinary Shares, at an average price of $21.7102. Following the cancellation of these shares, the Co
Read more →-ICLR
May 25, 2012May, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 24 May, 2012 it purchased for cancellation 30,000
the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 24 May, 2012 it purchased for cancellation 30,000 Ordinary Shares, at an average price of $21.4428. the cancellation of these shares, the Company will have 60,001,
Read more →-ICLR
May 23, 2012May, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 22 May, 2012 it purchased for cancellation 20,800
the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 22 May, 2012 it purchased for cancellation 20,800 Ordinary Shares, at an average price of $21.8164. the cancellation of these shares, the Company will have 60,048,
Read more →-ICLR
May 21, 2012May, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 18 May, 2012 it purchased for cancellation 20,000
the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 18 May, 2012 it purchased for cancellation 20,000 Ordinary Shares, at an average price of $21.864. the cancellation of these shares, the Company will have 60,094,2
Read more →-ICLR
May 18, 2012ICON p.l.c. and Subsidiaries Annual Report Year ended 31 December 2011 Registered number 145835 Directors' Report and Consolidated Financial Statements Contents Page Directors and Other Information 2 Directors' Report 3
ICON p.l.c. and Subsidiaries Year ended 31 December 2011 Registered number145835 Directors' Report and Consolidated Financial Statements Contents Page Directors and Other Information 2 Directors' Report 3 Operating and Financial Review 7 Board of Directors and Senior Manageme
Read more →-ICLR
May 18, 2012May, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 17 May, 2012 it purchased for cancellation 9,700
Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 17 May, 2012 it purchased for cancellation 9,700 Ordinary Shares, at an average price of Following the cancellation of these
Read more →-ICLR
May 16, 2012May, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 15 May, 2012 it purchased for cancellation 38 Ord
the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 15 May, 2012 it purchased for cancellation 38 Ordinary Shares, at an average price of $22.00. the cancellation of these shares, the Company will have 60,117,969 O
Read more →-ICLR
May 11, 2012May, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 10 May, 2012 it purchased for cancellation 2,700
Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 10 May, 2012 it purchased for cancellation 2,700 Ordinary Shares, at an average price of $21.9956. Following the cancellation of these shares, the Com
Read more →-ICLR
May 9, 2012May, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 8 May, 2012 it purchased for cancellation 9,048 O
Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 8 May, 2012 it purchased for cancellation 9,048 Ordinary Shares, at an average price of Following the cancellation of these
Read more →-ICLR
May 4, 2012May, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 3 May, 2012 it purchased for cancellation 600 Ord
Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 3 May, 2012 it purchased for cancellation 600 Ordinary Shares, at an average price of $22.00. Following the cancellation of these shares, the Company
Read more →-ICLR
May 1, 2012May, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 30 April, 2012 it purchased for cancellation 40,7
Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 30 April, 2012 it purchased for cancellation 40,700 Ordinary Shares, at an average price of $22.00. Following the cancellation of these shares, the Co
Read more →-ICLR
Apr 24, 2012st Quarter Results DUBLIN--(BUSINESS WIRE)
DUBLIN--(BUSINESS WIRE)--April 24, 2012-- ICON reports a 10% increase in first quarter 2012 revenue to $252m, up 10% year on year, EPS of 15 cents, net new business awards of $385 million and a B:B of 1.5. (NASDAQ:ICLR) (ISIN:IE0005711209) Highlights - First Quarter Fiscal 20
Read more →-ICLR
Feb 28, 2012ICON Acquires PriceSpective Leading Value Strategy Consultancy Deepens ICON's Pricing and Market Access Capabilities DUBLIN--(BUSINESS WIRE)
Acquires PriceSpective Value Strategy Consultancy Deepens ICON's Pricing and Market Access DUBLIN--(BUSINESS WIRE)--February 28, 2012--ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and me
Read more →-ICLR
Feb 16, 2012ICON reports fourth quarter 2011 revenue of $243m, up 5% year on year, and EPS of $0.07. Backlog increases 19%. (NASDAQ:ICLR) (ISIN:IE0005711209) Highlights - Fourth Quarter and Full year ended December 31 2011. * Q4 net
reports fourth quarter 2011 revenue of $243m, up 5% year on year, and EPS of $0.07. Backlog increases 19%. (NASDAQ:ICLR) (ISIN:IE0005711209) - Fourth Quarter and Full year ended December 31 2011. revenues increased 5% year on year to $243 million. FY 2011 net revenue increase
Read more →-ICLR
Jan 17, 2012January, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 13 January, 2012 it purchased for cancellatio
Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 13 January, 2012 it purchased for cancellation 700 Ordinary Shares, at an average price of $17.9793. Following the cancellation of these shares, the C
Read more →-ICLR
Jan 10, 2012January, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 9 January, 2012 it purchased for cancellation
Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 9 January, 2012 it purchased for cancellation 10,800 Ordinary Shares, at an average price Following the cancellation of thes
Read more →-ICLR
Jan 9, 2012ICON Selected by Shire plc's Specialty Pharmaceuticals division as Global Strategic Partner for Clinical Research and Central Laboratory Services DUBLIN--(BUSINESS WIRE)
Selected by Shire plc's Specialty Pharmaceuticals division as Global Strategic Partner for Clinical Research and Central Laboratory Services DUBLIN--(BUSINESS WIRE)--January 9, 2012--ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development serv
Read more →-ICLR
Jan 6, 2012January, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 5 January, 2012 it purchased for cancellation
Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 5 January, 2012 it purchased for cancellation 19,300 Ordinary Shares, at an average price of $17.0321. Following the cancellation of these shares, the
Read more →-ICLR
Jan 4, 2012January, 2012 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 3 January, 2012 it purchased for cancellation
Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 3 January, 2012 it purchased for cancellation 5,300 Ordinary Shares, at an average price of $17.0377. Following the cancellation of these shares, the
Read more →-ICLR
Dec 30, 2011December, 2011 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 29 December, 2011 it purchased for cancellat
Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 29 December, 2011 it purchased for cancellation 24,351 Ordinary Shares, at an average price of $16.8833. Following the cancell
Read more →-ICLR
Dec 28, 2011December, 2011 ICON plc Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 27 December, 2011 it purchased for cancellat
Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 27 December, 2011 it purchased for cancellation 14,515 Ordinary Shares, at an average Following the cancellation of these sh
Read more →-ICLR
Dec 27, 2011ICON Announces Dr. Anthony Murphy To Retire From Board of Directors DUBLIN--(BUSINESS WIRE)
Announces Dr. Anthony Murphy To Retire From Board of Directors DUBLIN--(BUSINESS WIRE)--December 27, 2011--ICON plc., (NASDAQ:ICLR)(ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, tod
Read more →-ICLR
Dec 20, 2011ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 19 December, 2011 it purchased for cancellation 144 Ordina
ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 19 December, 2011 it purchased for cancellation 144 Ordinary Shares, at an average price of $15.94. Following the
Read more →-ICLR
Dec 16, 2011ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 15 December, 2011 it purchased for cancellation 30,000 Ord
ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 15 December, 2011 it purchased for cancellation 30,000 Ordinary Shares, at an average price of $16.0638. Followin
Read more →-ICLR
Dec 14, 2011ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 13 December, 2011 it purchased for cancellation 30,000 Ord
ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 13 December, 2011 it purchased for cancellation 30,000 Ordinary Shares, at an average price of $16.1374. Followin
Read more →-ICLR
Dec 13, 2011ICON Acquires BeijingWits Medical Consulting Ltd Acquisition Strengthens ICON's Presence & Capabilities in China DUBLIN--(BUSINESS WIRE)
ICON Acquires BeijingWits Medical Consulting Ltd Acquisition Strengthens ICON's Presence & Capabilities in China DUBLIN--(BUSINESS WIRE)--December 13, 2011--ICON plc, (NASDAQ: ICLR) (ISIN: IE0005711209), a global provider of outsourced development services to the pharmaceutical
Read more →-ICLR
Dec 12, 2011ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 9 December, 2011 it purchased for cancellation 30,000 Ordi
ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 9 December, 2011 it purchased for cancellation 30,000 Ordinary Shares, at an average price of $16.2103. Following
Read more →-ICLR
Dec 9, 2011ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 8 December, 2011 it purchased for cancellation 30,000 Ordi
ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 8 December, 2011 it purchased for cancellation 30,000 Ordinary Shares, at an average price of $16.1418. Following
Read more →-ICLR
Dec 7, 2011ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 6 December, 2011 it purchased for cancellation 30,000 Ordi
ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 6 December, 2011 it purchased for cancellation 30,000 Ordinary Shares, at an average price of $16.6469. Following
Read more →-ICLR
Dec 5, 2011ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 2 December, 2011 it purchased for cancellation 30,000 Ordi
ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 2 December, 2011 it purchased for cancellation 30,000 Ordinary Shares, at an average price of $16.737. Following
Read more →-ICLR
Dec 2, 2011ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 1 December, 2011 it purchased for cancellation 30,000 Ordi
ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 1 December, 2011 it purchased for cancellation 30,000 Ordinary Shares, at an average price of $16.8237. Following
Read more →-ICLR
Nov 30, 2011ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 29 November, 2011 it purchased for cancellation 40,000 Ord
ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 29 November, 2011 it purchased for cancellation 40,000 Ordinary Shares, at an average price of $16.6207. Followin
Read more →-ICLR
Nov 28, 2011ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 25 November, 2011 it purchased for cancellation 24,017 Ord
ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 25 November, 2011 it purchased for cancellation 24,017 Ordinary Shares, at an average price of $16.8805. Followin
Read more →-ICLR
Nov 25, 2011ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 23 November, 2011 it purchased for cancellation 3,810 Ordi
ICON plc: Purchase of Own Securities Further to the announcement on 22 November, 2011 of a share repurchase programme, ICON plc ("the Company") announces that on 23 November, 2011 it purchased for cancellation 3,810 Ordinary Shares, at an average price Following the cancellat
Read more →-ICLR
Nov 22, 2011ICON plc: Commencement of Share Repurchase Programme DUBLIN--(BUSINESS WIRE)
Commencement of Share Repurchase Programme DUBLIN--(BUSINESS WIRE)--November 22, 2011--ICON plc (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it
Read more →-ICLR
Nov 1, 2011ICON Names New Global Head of Clinical Research Services Experienced Industry Executive Dr. Steve Cutler to Join ICON Leadership Team DUBLIN--(BUSINESS WIRE)
Names New Global Head of Clinical Research Services Industry Executive Dr. Steve Cutler to Join ICON Leadership Team DUBLIN--(BUSINESS WIRE)--November 1, 2011--ICON plc.(NASDAQ:ICLR)(ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutica
Read more →-ICLR
Oct 27, 2011ICON Reports Q3 revenue growth of 7% to $241 million and net new business of $431 million. (NASDAQ:ICLR) (ISIN:IE0005711209) Highlights - Third Quarter Fiscal 2011 * Net revenue of $241 million, a 7% increase year on yea
Reports Q3 revenue growth of 7% to $241 million and net new business of $431 million. (NASDAQ:ICLR) (ISIN:IE0005711209) - Third Quarter Fiscal 2011 revenue of $241 million, a 7% increase year on year. EPS of -4c after restructuring charges of $4.8m. Excluding these restructu
Read more →-ICLR
Sep 7, 2011ICON Announces Peter Gray To Retire As CEO Ciaran Murray named as his successor and appointed to Board DUBLIN--(BUSINESS WIRE)
Announces Peter Gray To Retire As CEO Murray named as his successor and appointed to Board DUBLIN--(BUSINESS WIRE)--September 7, 2011--ICON plc (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and med
Read more →-ICLR
Aug 30, 2011ICON Selected as a Preferred Provider for Early Phase Clinical Development by Bristol-Myers Squibb Agreement Builds on Existing Strategic Partnership for Global Clinical Development DUBLIN--(BUSINESS WIRE)
Selected as a Preferred Provider for Early Phase Clinical Development by Bristol-Myers Squibb Builds on Existing Strategic Partnership for Global Clinical Development DUBLIN--(BUSINESS WIRE)--August 30, 2011--ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of o
Read more →-ICLR
Jul 20, 2011ICON Reports Second Quarter 2011 Net New Business of $310 million, Revenue of $233 million and EPS of 21c (NASDAQ:ICLR) (ISIN:IE0005711209) Highlights - Second Quarter Fiscal 2011 * Net revenue of $233 million, a 4% incr
Reports Second Quarter 2011 Net New Business of $310 million, Revenue of $233 million and EPS of 21c (NASDAQ:ICLR) (ISIN:IE0005711209) - Second Quarter Fiscal 2011 revenue of $233 million, a 4% increase year on year. from operations was $15.5m. Operating margin was 7% busin
Read more →-ICLR
Jul 14, 2011ICON Acquires Firecrest Clinical Acquisition Enables ICON to Enhance Investigator Site Performance & Quality DUBLIN--(BUSINESS WIRE)
Acquires Firecrest Clinical ICON to Enhance Investigator Site Performance & Quality DUBLIN--(BUSINESS WIRE)--July 14, 2011--ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical devic
Read more →-ICLR
Jun 17, 2011Dear Shareholders and Stakeholders Overview The challenging market conditions that prevailed during 2009 continued into 2010 as our clients continued to seek ways to reduce costs and national governments endeavoured to r
Dear Shareholders and Stakeholders The challenging market conditions that prevailed during 2009 continued into 2010 as our clients continued to seek ways to reduce costs and national governments endeavoured to reduce healthcare budgets, including pharmaceutical prices. For th
Read more →-ICLR
May 26, 2011ICON Selected by Pfizer as a Global Strategic Partner for Clinical Research and Development ICON Selected For Strength of Services, Quality and Regulatory Compliance and Collaboration Expertise Dublin, Ireland
ICON Selected by Pfizer as a Global Strategic Partner for Clinical Research and Development ICON Selected For Strength of Services, Quality and Regulatory Compliance and Collaboration Expertise Dublin, Ireland, May 26, 2011 - ICON plc, (NASDAQ: ICLR; ISIN: IE0005711209), a g
Read more →-ICLR
Apr 21, 2011ICON Reports First Quarter 2011 Revenue up 5% to $229 Million and EPS of 21c Highlights - First Quarter Fiscal 2011 * Net revenue of $229 million, a 5% increase year on year, 6% at constant currency. * Income from operat
Reports First Quarter 2011 Revenue up 5% to $229 Million and EPS of 21c - First Quarter Fiscal 2011 revenue of $229 million, a 5% increase year on year, 6% at constant from operations was $16m, before restructuring charges. Operating margin before the restructuring charges wa
Read more →-ICLR
Feb 24, 2011ICON Reports Full-Year 2010 Revenue of $900m and EPS of $1.44 Highlights - Full Year 2010 and Fourth Quarter ended December 31. * 2010 net revenue increased 1.4% to $900 million, or 3.1% on a constant currency basis. Q4
Reports Full-Year 2010 Revenue of $900m and EPS of $1.44 - Full Year 2010 and Fourth Quarter ended December 31. net revenue increased 1.4% to $900 million, or 3.1% on a constant currency basis. Q4 net revenues increased 2.1% or 5.6% on a constant currency basis to $232 millio
Read more →-ICLR
Jan 14, 2011ICON Acquires Oxford Outcomes Leading International Health Outcomes Consultancy to become part of New Late Phase and Outcomes Research Unit Dublin, Ireland, January 14 th , 2011 - ICON plc, (NASDAQ:ICLR) (ISIN:IE00057112
ICON Acquires Oxford Outcomes Leading International Health Outcomes Consultancy to become part of New Late Phase and Outcomes Research Unit Dublin, Ireland, January 14th, 2011 - ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services
Read more →-ICLR
Nov 29, 2010Icon Reports Revenues of $225 Million up 2% on Prior Year (Nasdaq:ICLR) (ISIN:IE0005711209) DUBLIN--(BUSINESS WIRE)
Reports Revenues of $225 Million up 2% on Prior Year (Nasdaq:ICLR) DUBLIN--(BUSINESS WIRE)--October 21, 2010-- Highlights - Third Quarter 2010 * Net revenue of $225 million, a 2% increase vs. Q3 2009 * Operating margin of 12.0% before central lab and foreign exchange * Opera
Read more →-ICLR
Sep 30, 2010ICON p.l.c. and Subsidiaries Annual Report Year ended 31 December 2009 Registered number 145835 Directors' Report and Consolidated Financial Statements Contents Page Directors and Other Information 2 Directors' Report 3
ICON p.l.c. and Subsidiaries Year ended 31 December 2009 Registered number145835 Directors' Report and Consolidated Financial Statements Contents Page Directors and Other Information 2 Directors' Report 3 Report on Directors' Remuneration 16 Directors' Responsibilities Stat
Read more →-ICLR
Jul 27, 2010ICON Reports Revenues Up 2% And Strong New Business Wins Highlights - Second Quarter 2010 * Net revenue of $224 million a 2% increase on Q2 2009 * Operating margin of 11.5% compared to 13.3% last year * EPS of 38 cent, t
Reports Revenues Up 2% And Strong New Business Wins - Second Quarter 2010 revenue of $224 million a 2% increase on Q2 2009 Operating margin of 11.5% compared to 13.3% last year 38 cent, the same as last year business wins of $320m represent a strong book-to-bill ratio of 1.4
Read more →-ICLR
Jul 20, 2010ICON Shareholders Pass All Resolutions at Its Annual General Meeting DUBLIN--(BUSINESS WIRE)
Shareholders Pass All Resolutions at Its Annual General Meeting DUBLIN--(BUSINESS WIRE)--July 20, 2010--ICON plc, advises that all resolutions recommended by the Board at the Annual General Meeting of the Shareholders of the Company, held on 19 July 2010, were duly passed by
Read more →-ICLR
Jul 8, 2010ICON Extends AGM Proxy Return Deadline for Holders of American Depositary Shares DUBLIN--(BUSINESS WIRE)
Extends AGM Proxy Return Deadline for Holders of American Depositary DUBLIN--(BUSINESS WIRE)--July 8, 2010--ICON plc wish to advise that the proxy return deadline for holders of American Depositary Shares ("ADS's") to appoint proxies to vote on the resolutions to be put before
Read more →-ICLR
Jun 16, 2010THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you should consult with your independent financial adviser who, if you are taking advice in Ireland,
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you should consult with your independent financial adviser who, if you are taking advice in Ireland, is authorised or exempted under the European Communities (
Read more →-ICLR
Apr 27, 2010ICON Reports Solid First Quarter, with EPS up 6% Year on Year Highlights - First Quarter Fiscal 2010 * First quarter net revenues were $219 million. * Income from operations was $26.8 million. * Operating margin of 12.2%
Reports Solid First Quarter, with EPS up 6% Year on Year - First Quarter Fiscal 2010 quarter net revenues were $219 million. from operations was $26.8 million. Operating margin of 12.2%. earnings per share increased by 2 cent on last year to 37c. business wins in the quarte
Read more →-ICLR
Feb 25, 2010ICON reports Full-Year 2009 EPS growth of 18% and announces Revenue and EPS Guidance for 2010 Highlights - Full Year Fiscal 2009 and Fourth Quarter * Full year net revenues increased 3% to $888 million. Fourth quarter ne
reports Full-Year 2009 EPS growth of 18% and announces Revenue and EPS - Full Year Fiscal 2009 and Fourth Quarter year net revenues increased 3% to $888 million. quarter net revenues increased 3% over the comparative quarter, to $227 year operating income increased by 17% to
Read more →-ICLR
Dec 17, 2009Dr. John Climax Announces His Retirement as Chairman of ICON plc - Dr. Bruce Given Elected to Succeed Him DUBLIN--(BUSINESS WIRE)
Climax Announces His Retirement as Chairman of ICON plc - Dr. Bruce Given Elected to Succeed Him DUBLIN--(BUSINESS WIRE)--December 17, 2009--ICON Plc (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology a
Read more →-ICLR
Dec 4, 2009ICON Receives Warning Letter Relating to Two Studies DUBLIN--(BUSINESS WIRE)
Receives Warning Letter Relating to Two Studies DUBLIN--(BUSINESS WIRE)--December 4, 2009--ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), today announced it has received a warning letter from the U.S. Food and Drug Administration (FDA) regarding clinical study management servic
Read more →-ICLR
Oct 21, 2009ICON Reports 14% Increase in EPS, and Raises Earnings Guidance for 2009 Highlights - Third Quarter Fiscal 2009 * Net revenue of $220 million. * Income from operations increased by 12%, to $30.4 million. * Operating margi
Reports 14% Increase in EPS, and Raises Earnings Guidance for 2009 - Third Quarter Fiscal 2009 revenue of $220 million. from operations increased by 12%, to $30.4 million. Operating margins expanded from 12% to 13.8%. increased by 14% to 40 cents. new business wins of $296
Read more →-ICLR
Jul 23, 2009ICON plc: Results of Annual General Meeting DUBLIN--(BUSINESS WIRE)
Results of Annual General Meeting DUBLIN--(BUSINESS WIRE)--July 23, 2009--ICON advises that all resolutions recommended by the Board at the Annual General Meeting of the Company held on 20 July 2009 were duly passed. These resolutions were set out in the Notice of the Annual
Read more →-ICLR
Jul 22, 2009ICON Reports 22% Increase in EPS and Strong Cash Flows (NASDAQ:ICLR) (ISIN:IE0005711209) Highlights - Second Quarter Fiscal 2009 * Net revenue of $220 million. * Income from operations increased by 20%, to $29.3 million,
Reports 22% Increase in EPS and Strong Cash Flows (NASDAQ:ICLR) - Second Quarter Fiscal 2009 revenue of $220 million. from operations increased by 20%, to $29.3 million, before one time net Operating margins before one time net charges expanded to 13.3% from 11.2% and EPS on
Read more →-ICLR
Jul 9, 2009Letter to Shareholders of ICON plc DUBLIN--(BUSINESS WIRE)
Shareholders of ICON plc DUBLIN--(BUSINESS WIRE)--July 9, 2009-- We wish to advise that we have extended the voting deadline for the resolutions to be put before the shareholders at our Annual General Meeting on July 20, 2009, to allow shareholders further time to consider t
Read more →-ICLR
Jul 9, 2009ICON Acquires Veeda Laboratories Limited Expands ICON's Biomarker and Immunoassay Capabilities in Europe DUBLIN--(BUSINESS WIRE)
Acquires Veeda Laboratories Limited ICON's Biomarker and Immunoassay Capabilities in Europe DUBLIN--(BUSINESS WIRE)--July 9, 2009--ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medica
Read more →-ICLR
Feb 23, 2009ICON reports Full-Year 2008 revenue growth of 37% operating income growth of 44% and EPS growth of 38% (NASDAQ:ICLR) (ISIN:IE0005711209) Highlights - Full Year Fiscal 2008 and Fourth Quarter Full year net revenues increa
reports Full-Year 2008 revenue growth of 37% operating income growth of 44% and EPS growth of 38% (NASDAQ:ICLR) (ISIN:IE0005711209) - Full Year Fiscal 2008 and Fourth Quarter year net revenues increased 37% to $865 million. quarter net revenues increased 22% over the comparat
Read more →-ICLR
Jan 9, 2009ICON Issues Financial Guidance for 2009 and Updates Guidance for 2008 (NASDAQ:ICLR) (ISIN:IE0005711209) Dublin, Ireland--(BUSINESS WIRE)
Issues Financial Guidance for 2009 and Updates Guidance for 2008 Dublin, Ireland--(BUSINESS WIRE)--January 9, 2009--ICON (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced fi
Read more →-ICLR
Jan 8, 2009ICON plc Acquires Remaining 30% Stake in Beacon Bioscience Inc. DUBLIN, Ireland--(BUSINESS WIRE)
Acquires Remaining 30% Stake in Beacon Bioscience Inc. DUBLIN, Ireland--(BUSINESS WIRE)--January 8, 2009--ICON plc (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today
Read more →-ICLR
Dec 15, 2008ICON Announces Guidance date for 2009 DUBLIN, Ireland--(BUSINESS WIRE)
Announces Guidance date for 2009 DUBLIN, Ireland--(BUSINESS WIRE)--December 15, 2008--ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it
Read more →-ICLR
Nov 18, 2008Lilly Selects ICON to Manage its Clinical Data Management Business Outside the US DUBLIN, Ireland--(BUSINESS WIRE)
Selects ICON to Manage its Clinical Data Management Business Outside the DUBLIN, Ireland--(BUSINESS WIRE)--November 18, 2008-- Lilly Selects ICON to Manage its Clinical Data Management Business Strategic Agreement Spans More Than 36 Countries Dublin, Ireland, November 18th, 2
Read more →-ICLR
Nov 14, 2008ICON Acquires Prevalere Life Sciences Inc Expands Bioanalytical and Immunoassay Capabilities into the United States DUBLIN, Ireland--(BUSINESS WIRE)
Acquires Prevalere Life Sciences Inc Bioanalytical and Immunoassay Capabilities into the United States DUBLIN, Ireland--(BUSINESS WIRE)--November 14, 2008--ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical,
Read more →-ICLR
Oct 21, 2008Icon Reports 35% Increase in Revenue and 45% Increase in Operating Income Highlights - Third Quarter Fiscal 2008 Net revenues increased 35%, to $225.5 million Income from operations increased by 45%, to $27.1 million Ope
Reports 35% Increase in Revenue and 45% Increase in Operating Income Third Quarter Fiscal 2008 revenues increased 35%, to $225.5 million from operations increased by 45%, to $27.1 million margin increased to 12% from 11.2% earnings per share increased by 46% to 35 cents bus
Read more →-ICLR
Aug 8, 2008ICON Announces Completion of " Stock Split " DUBLIN, Ireland--(BUSINESS WIRE)-- ICON (NASDAQ: ICLR) (ISIN: IE0005711209) , a global provider of outsourced development services to the pharmaceutical, biotechnology and med
Announces Completion of "Stock DUBLIN, Ireland--(BUSINESS WIRE)--ICON (NASDAQ: ICLR) (ISIN: IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has completed its bonus
Read more →-ICLR
Jul 31, 2008ICON announces ADS Payment Date and NASDAQ Ex-Date for " Stock Split " DUBLIN, Ireland--(BUSINESS WIRE)-- ICON (NASDAQ:ICLR) (ISIN: IE0005711209) , a global provider of outsourced development services to the pharmaceutic
announces ADS Payment Date and NASDAQ Ex-Date for "Stock DUBLIN, Ireland--(BUSINESS WIRE)--ICON (NASDAQ:ICLR) (ISIN: IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced its pay
Read more →-ICLR
Jul 10, 2008Letter to Shareholders of ICON plc Dear All In response to the negative voting recommendations on our proposed share award plans made by Institutional Shareholder Services Inc and which we addressed in our communication
to Shareholders of ICON plc response to the negative voting recommendations on our proposed share award plans made by Institutional Shareholder Services Inc and which we addressed in our communication to you on July 8, we have been in direct contact with a substantial percent
Read more →-ICLR
Jul 9, 2008Letter to Shareholders of ICON plc. Dear All Following feedback from some of our shareholders regarding certain provisions in our proposed share award plans we have agreed to recommend to the Board the following amendmen
Shareholders of ICON plc. feedback from some of our shareholders regarding certain provisions in our proposed share award plans we have agreed to recommend to the Board the following amendments to the plans in the next twelve months. We will recommend to our Board that the 20
Read more →-ICLR
Jul 8, 2008Letter to Shareholders of ICON plc. Dear All We are disappointed to note that in its recently published voting recommendations document Institutional Shareholder Services Inc ("ISS") are recommending a no vote on resolut
Shareholders of ICON plc. disappointed to note that in its recently published voting recommendations document Institutional Shareholder Services Inc ("ISS") are recommending a no vote on resolutions 6, 7 and 8 at the Company's forthcoming AGM on July 21, 2008 in which the Boa
Read more →-ICLR
May 29, 2008ICON plc announces appointment of Professor Dermot Kelleher to the Board of Directors. (NASDAQ:ICLR) (ISIN: IE0001827041) Dublin, Ireland, May 28 2008 - ICON plc, a global provider of outsourced development services to t
plc announces appointment of Professor Dermot Kelleher to the Board of (ISIN: IE0001827041) Dublin, Ireland, May 28 2008 - ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the a
Read more →-ICLR
Mar 2, 2007Chairman Dr. John Climax ICON Corporate Dev President Bill Taaffe CEO Peter Gray CFO Ciaran Murray ICON Development Solutions President Dr Thomas Frey ICON Central Laboratories President Bob Scott-Edwards ICON Contractin
plc Global Organization plc Global Organization contained herein including, without limitation, statements containing "believes," "anticipates," "intends," "expects" and words of similar import, forward-looking statements concerning the Company's performance, financial cond
Read more →-ICLR
Jan 10, 2007ICON raises 2006 guidance and issues financial guidance for 2007 Highlights * 2006 Revenue guidance raised to $448 - $452 million. * 2006 EPS guidance raised to $1.28 - $1.30. * Revenue forecast to grow 20% in 2007, comp
raises 2006 guidance and issues financial guidance for Ireland, December 15, 2006 - ICON (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today raised its existing 2006 guidance and announc
Read more →-ICLR
Aug 1, 2006ICON plc American Depositary Shares Representing Ordinary Shares ( par value 0.06 per share ) ____________________ Form of Underwriting Agreement ____________________ , 2006 William Blair & Company, L.L.C., Bear Stearns
American Depositary Shares (par value 0.06 per share) ____________________ Form of Underwriting Agreement ____________________ William Blair & Company, L.L.C., Bear Stearns & Co. Inc., Jefferies & Company, Inc., c/o William Blair & Company, L.L.C. 222 West Adams Street,
Read more →-ICLR
Apr 19, 2006ICON Files Registration Statement for American Depositary Shares Dublin, Ireland
ICON Files Registration Statement for American Depositary Shares Dublin, Ireland, April 19, 2006 - ICON plc (NASDAQ: ICLR) announced today that it has filed a shelf registration statement with the U.S. Securities and Exchange Commission covering the offer and sale of up to 125,0
Read more →-ICLR
Jan 11, 2006ICON reports record net new business awards of $140 million and a 20% increase in EPS for the Second Quarter FY 2006 (NASDAQ:ICLR) Highlights - Second Quarter Fiscal 2006, ending
net new business awards of $140 million and a 20% increase in EPS for the Second Quarter FY 2006 (NASDAQ:ICLR) - Second Quarter Fiscal 2006, ending November 30, 2005. Ireland, January 10, 2006 - ICON plc (NASDAQ: ICLR), a global contract clinical research organisation, which
Read more →-ICLR
Sep 27, 2005ICON reports 10% increase in net revenues and EPS of 45 cents. (NASDAQ:ICLR) Highlights First Quarter Fiscal 2006 * First Quarter net revenues increased 10% over the first quarter of fiscal 2005 to $85.9 mi
ICON reports 10% increase in net revenues and EPS of 45 cents. (NASDAQ:ICLR) Highlights First Quarter Fiscal 2006 Dublin, Ireland, September 27, 2005 ICON plc (NASDAQ: ICLR), a global contract clinical research organisation, which has over 2,800 employees providing services to
Read more →-ICLR
Aug 30, 2005ICON Announces New Appointments Dublin, Ireland, Monday
ICON Announces New Appointments Dublin, Ireland, Monday, August 30, 2005 ICON plc (NASDAQ: ICLR) today announced the appointment of Mr. Sean Leech, currently Chief Financial Officer, to the position of Executive Vice President Commercial and Organisational Development. This new
Read more →-ICLR
Aug 2, 2005ICON reports 10% increase in net revenues and EPS of 42 cents. (NASDAQ:ICLR) Highlights - Fourth Quarter and Full Year Fiscal 2005 * Fourth quarter net revenues increased 10% over the fourth quarter of fiscal 2004 to $86
icon6k-080405ex991.txt ICON reports 10% increase in net revenues and EPS of 42 cents. (NASDAQ:ICLR) Highlights - Fourth Quarter and Full Year Fiscal 2005 * Fourth quarter net revenues increased 10% over the fourth quarter of fiscal 2004 to $86.0 million and also increased 10%
Read more →-ICLR
Jan 6, 2005ICON reports a 9% increase in net revenues, EPS of $0.41 and net new business awards of $120 million for the Second Quarter FY 2005 (NASDAQ:ICLR) Highlights - Second Quarter Fiscal 2005 * Second quarter net revenues incr
icon6k-010605ex991.txt ICON reports a 9% increase in net revenues, EPS of $0.41 and net new business awards of $120 million for the Second Quarter FY 2005 (NASDAQ:ICLR) Highlights - Second Quarter Fiscal 2005 * Second quarter net revenues increased 9% over the second quarter
Read more →-ICLR
Sep 28, 2004ICON Reports Strong Results with 24% increase in operating income in First Quarter FY 2005 (NASDAQ:ICLR) Highlights - First Quarter Fiscal 2005 * First Quarter net revenues increased 14% over the first quarter of fiscal
icon6k092804ex99-1.txt ICON Reports Strong Results with 24% increase in operating income in First Quarter FY 2005 (NASDAQ:ICLR) Highlights - First Quarter Fiscal 2005 * First Quarter net revenues increased 14% over the first quarter of fiscal 2004 to $78.3 million. * Income
Read more →Competitive Position
How ICLR ranks across every disease it competes inCompetitive Position is a premium feature
See how ICLR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial